|Marvin Gee||3T Biosciences|
CoFounder & Head, Target Discovery
Biology at the California Institute of Technology in 2013, where he published and patented work engineering T cell receptors for adoptive T cell therapy in the laboratory of David Baltimore. Following, he received his Ph.D. in Immunology at Stanford University in the laboratory of K. Christopher Garcia in 2017, publishing work on technology to identify the specificities of T cell receptors for application in oncology and further work on the molecular- and systems biology-focused characterization of T cell receptor recognition of immunological targets. At Stanford, Marvin received his PhD degree with an additional core focus in Computational Immunology. Marvin has had prior work experience at the National Cancer Institute. His primary focuses are in immunology, structural biology, protein engineering, systems biology, bioinformatics, and algorithms for the application of therapeutic- and early- discovery in immuno-oncology. He is currently Head of Target Discovery at 3T Biosciences since co- -founding the company in 2017.
|Tariq Ghayur, PhD||Abbvie|
Distinguished Research Fellow, Foundational Immunology
Tariq Ghayur received his PhD (1987) in Immunology from McGill University, Montreal, Canada and did his post-doctoral training at McGill (1987-’88) and Dana Farber Cancer Institute (1988-’90). He joined AbbVie Inc. in 1990. Tariq has worked on both small molecule and therapeutic antibody discovery programs and from 1998-2004 led two therapeutic antibody discovery project teams and delivered 2 drug development candidates. From 2011-2016, Tariq led the dual variable domain Ig (DVD – Ig™) Initiative and the Novel Biologics group at AbbVie. Currently, he leads the Foundational Immunology group. In addition to therapeutic antibodies, novel biologic formats and antibody generation technologies, his areas of interest are inflammation, intracellular trafficking, antigen processing and presentation, lymphocyte biology, cytokine biology and glyco-biology.
Senior Principal Research Scientist
Mike obtained his PhD in Chemistry from the University of Edinburgh in Prof. Bob Baxter’s lab and then moved to Brown University in RI to pursue postdoctoral research with Prof. David Cane on engineering polyketide synthases to produce “unnatural” natural products. He was an early employee of the biotech company Phylos Inc., founded by Brian Seed and Nobel Laureate Jack Szostak to advance the utility of mRNA display in the discovery of high affinity binding proteins through in vitro selection. There he successfully applied mRNA display towards the identification of drug-binding proteins using tissue-derived libraries. Since joining Abbott Laboratories in 2004 and now AbbVie, he has helped provide key molecular/cellular pharmacology support and project leadership to both small molecule and biologics drug discovery programs within Immunology Discovery. He currently leads a group within Global Biologics Discovery that is focused on the identification of novel biologic therapeutics to treat patients with cancer, autoimmune disease or neurological disorders.
I got my Bachelor’s in Chemistry and Philosophy at Creighton University in Omaha working in synthetic organic chemistry. I then went to the University of Minnesota, where I received my Ph.D. working under Will Pomerantz developing protein-observed fluorine NMR as a ligand discovery technique. Since then I’ve been working in the high-throughput protein engineering group at AbbVie Bioresearch Center to design, produce, and analyze proteins in high-throughput.
|Wendy Ritacco||Abbvie Bioresearch Center|
Senior Scientist III, Global Biologics
Wendy Ritacco is a Senior Scientist at Abbvie and specializes in design and optimization of conditionally activated biologics. She dedicated to the creation of efficacious treatments without deleterious side effects. She received her MS from Worcester Polytechnic Institute and has more than 25 years biopharmaceutical industry experience.
|Fiona Harding, PhD||AbbVie Biotherapeutics Inc|
Senior Research Fellow
Fiona Harding trained as an immunologist as the University of Rochester and the University of California, Berkeley. Her specialty is cellular and molecular immunology. Her postdoctoral activities included the characterization of the costimulatory molecule CD28 In Dr James P Allison’s lab. Fiona has over 25 years’ experience in biotechnology and industry, starting her career at GenPharm International (now Medimmune/AstraZeneca) characterizing early humanized mouse models that lead to the generation of the HuMab mouse. She developed and patented an in vitro screening method for the identification of immunogenic T cell epitopes in therapeutic proteins (the iMune Assay) while working at Genencor International (now DuPont). Fiona joined PDL in 2005 and has been working at Abbott/AbbVie since 2010. Fiona has worked on many programs and projects, and is currently leading multiple discovery, pre-clinical, and clinical stage immuno-oncology programs.
|Yoshiko Akamatsu||AbbVie Inc|
Senior Principal Research Scientist Biologics Discovery
Dr. Yoshiko Akamatsu received Ph.D. in Biophysics from Kyoto University and completed postdoctoral training at Harvard Medical School. She was an Associate Professor in the University of Tokushima, Japan, before she decided to move to the US to work at a biotech company in 2003. Since then, she has been conducting research in the area of antibody and protein engineering in PDL BioPharma, Facet Biotech, Abbott and Abbvie.
|Kevin Heyries, PhD||AbCellera Biologics Inc|
Co-Founder, Head, Business Development
Kevin Heyries holds a PhD in biochemistry (Uni. of Lyon) where he developed microfluidics for antibody analysis. During his postdoctoral work (Uni. of British Columbia), he developed high throughput microfluidics systems for digital PCR and single-cell genomics. Dr. Heyries was instrumental in the development of AbCellera’s technology, where he is now leading business development and strategy.
|Oleh Petriv, PhD||AbCheck|
Vice President, New Technology Development
Dr. Oleh Petriv received his PhD in Cell Biology at the University of Alberta in Canada. Later he studied design and manufacturing of microfluidic chips, worked on high-throughput single-cell PCR and sequencing methods. Oleh is one of the co-founders of AbCellera, a company focusing on monoclonal antibody discovery based in Canada. In 2018 he brought his experience of R&D and technology development to AbCheck and leads a team developing entirely new and unsurpassed methods of antibody discovery by functional criteria.
|Carlo Boutton||Ablynx a Sanofi Co|
Head, Nanobody Explorative Technologies
Carlo Boutton obtained his PhD in 1999 at the University of Leuven (Belgium) on a subject that investigated the physico-chemical behavior of proteins under high-electromagnetic (laser) fields. After his PhD he joined Algonomics (currently Lonza) where he contributed to the development of EpiBase: a platform to predict and identify T-cell epitopes in biologics. In 2003 he joined Tibotec (subsidiary of Johnson & Johnson) where he was involved in several anti-HIV and anti-HCV projects. He joined Ablynx in 2007 where he focused on improvements of the Nanobody platform and new therapeutic applications for Nanobodies, including bispecifics, immunotherapeutics and ADCs. After the acquisition of Ablynx by Sanofi he holds the position of Head Nanobody Explorative Technologies. Together with his team he is working on a next generation Nanobody platform.
|Ian Wilkinson||Absolute Antibody Ltd|
Ian’s background is firmly in the engineering and development of therapeutic antibodies. Having solved the first NMR structure of a human antibody fragment (UCB-Celltech, University of Leicester) Ian oversaw therapeutic research projects covering technology validation, drug discovery and optimization (MedImmune, AstraZeneca) before joining Absolute Antibody at its founding in 2012.
|Colby Souders, PhD||Abveris|
After his PhD in Cell and Molecular Biology from Texas A&M, Colby joined MassBiologics. There, he led programs to discover and advance mAbs for the prevention, treatment or diagnosis of infectious and endogenous diseases. He later joined the Kanyos Bio Protein Engineering team to develop therapeutics based on a novel antigen-specific immune tolerance platform. Colby joined Abveris Antibody as Chief Scientific Officer to usher in new antibody discovery tools and build a premium discovery engine.
|Nora Mineva, PhD||Adecto Pharmaceuticals|
Dr. Nora Mineva is the Chief Scientific Officer and a co-founder of Adecto Pharmaceuticals, a start-up developing the first targeted treatment against ADAM8-positive cancers and a companion diagnostic to identify patients who can benefit from it, with a focus on triple-negative breast cancer as the first indication. She holds a Ph.D. in Pathology and Laboratory Medicine from Boston University School of Medicine and a B.A./M.A. in Biology from Clark University. Dr. Mineva is involved in company management, business development, investor relations, and fundraising efforts in addition to therapeutic and diagnostic development. She is a graduate of the NIH I-Corps Business Training Program and MassBio’s MassConnect Entrepreneur Mentorship Program.
|Stewart Abbot||Adicet Bio Inc|
|Robert Pejchal, PhD||Adimab LLC|
Associate Director Antibody Engineering
I received my PhD from University of Michigan Ann Arbor in protein crystallography. I then did a postdoc at The Scripps Research Institute where I studied broadly neutralizing HIV-1 antibodies, solved crystal structures of such antibodies bound to viral envelope glycoproteins and peptide antigens. After taking a scientist position at Adimab LLC, my focus on antibody engineering blossomed into a bispecific antibody discovery and optimization and cell selection approaches for membrane protein targets. Currently, as Director of Antibody Engineering, my work on bispecifics and membrane protein targets continues alongside platform optimization, antibody format research and development, and developability.
|Daniel Olive||Aix Marseille University|
Head Tumor Immunology
D. Olive has been a pioneer and leader in the co-signalling field since 1990. His work is dedicated to tumor immunology with a major emphasis on innate immunity and co-signalling molecules. Selected major breakthroughs: 1) Identification of signaling pathways involved in CD28 and ICOS costimulatory molecules; 2) Demonstration that BTN3A1/CD277 is a major inducer of Vg9Vd2 response; 3) identification of the function of BTLA and HVEM in the regulation of immune function; 4) Identification of molecular mechanisms associated to NK cells impairment in AML patients; 5) first identification of alteration of NK cells in the tumor bed in breast and prostate cancer; 6) First in man clinical trial using anti-KIR mAbs in AML patients; 7) Deciphering of of ICOS ICOSL interaction in the regulation of Tregs in lymphomas.
|Jonathan Lai, PhD||Albert Einstein College of Medicine|
Associate Professor, Biochemistry
Jonathan Lai is Professor of Biochemistry at the Albert Einstein College of Medicine in the Bronx, NY. Dr. Lai received his undergraduate training in Biochemistry at Queen’s University in Kingston, Ontario, Canada, then obtained his PhD in Chemistry and Biophysics at the University of Wisconsin, Madison in 2004. From 2004-2007, he was Helen Hay Whitney Post-Doctoral Fellow in Biological Chemistry at Harvard Medical School. He began his independent lab at the Albert Einstein College of Medicine in 2007. His group has broad interests in peptide, protein, and antibody engineering with application of these methods to discovery of new immunotherapies and vaccines.
|Mark Ma||Alexion Pharmaceuticals Inc|
Executive Director, Bioanalytical Development
Mark Ma is Executive Director of Bioanalytical Development at Alexion Pharmaceuticals. His group provides bioanalytical and Biomarker support to Alexion projects, including large molecule, small molecule, and RNAs. Before Alexion, Mark was a director of large molecule bioanalytical sciences at Amgen. Mark has been active in American Association of Pharmaceutical Scientists (AAPS) and service as chair of PK assay group within Ligand Binding Assay committee. Mark had held several academic research positions with UCLA and MMRI. His professional career outside of industry includes being a reviewer for several scientific journals and giving lectures to local colleges/universities.
|Peter Ellmark||Alligator Bioscience AB|
Vice President Discovery
Peter Ellmark joined Alligator Bioscience in 2008 and is VP Discovery since 2018. He holds a PhD and an associate professorship in Immunotechnology at Lund University and has more than 15 years’ experience of developing antibodies for immunotherapy of cancer. Dr. Ellmark´s research interest is focused on developing mono- and bispecific antibodies for tumor directed immunotherapy of cancer.
|Thomas Van Blarcom||Allogene Therapeutics|
Senior Director & Head
Tom Van Blarcom received his Ph.D. in Chemical Engineering from The University of Texas at Austin, where he worked on the development and application of cell surface display systems for antibody engineering. Afterwards he joined the Protein Engineering Department at Pfizer’s South San Francisco location where he continued to develop novel technologies for antibody engineering including cell surface display, synthetic antibody library design and library synthesis technologies and applied them to improve the development of therapeutic monoclonal antibodies, bispecific antibodies and CAR T cells. Since then, he has continued his work on CAR T cells by joining Allogene Therapeutics, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T cell (AlloCAR TTM) therapies for cancer. At Allogene, Tom oversees all protein engineering activities and contributes to various aspects of CAR T cell design and engineering.
|Tina Liu, MBA||Ally Therapeutics|
Co-Founder and CEO
Tina serves as co-founder/CEO of Ally Therapeutics, an innovative company dedicated to solving the immune response barriers for gene therapy. She spun the company out of the Wyss Institute at Harvard, where she had supported the foundational research as an Entrepreneur-in-Residence. Prior, Tina was a private equity investor at TPG Capital, where she evaluated potential investments $1Bn+ in size across commercial pharma and other sectors of the healthcare industry. Before that, Tina was an investment banker at Morgan Stanley, where she advised healthcare companies on key transactions including mergers and acquisitions, equity and debt financings, and other strategic alternatives. Tina received her MBA with Distinction from Harvard Business School and her BA, magna cum laude, from Harvard College.
|Aude Segaliny, PhD||Amberstone Biosciences|
Group Leader, Assay Biology & Scientific Liaison, Assay Biology,
Dr. Segaliny is a founding scientist of Amberstone Biosciences. She currently serves as the Head of Assay Biology and Scientific Liaison at Amberstone, where she spearheaded the efforts in developing cutting-edge microfluidic-based approaches to enable the discovery of transformative immunotherapeutics. She has 10+ years of experience in cancer biology/immunology.
|Tara Arvedson, PhD||Amgen|
Director, Oncology Research
Tara Arvedson, Executive Director in Oncology Research at Amgen, has led multiple T cell therapeutic programs and is currently responsible for a large portfolio of T cell therapeutic assets and platform strategy. She received her Ph.D. at Caltech and was later a Damon Runyon Cancer Research Fellow at UC San Diego.
|MeiYun Zhang||Amgen Asia R&D Center|
Principal Scientist, Antibody Discovery
Dr. Mei-Yun Zhang obtained her B.A. in Genetics and M.S. in Biochemistry from China Agricultural University, and Ph.D. in Natural Science from Aachen Technical University, Germany. After a postdoc training in NCI, NIH, she was promoted to Scientist. She was appointed Assistant Professor and served as a Faculty member in the Department of Microbiology, The University of Hong Kong. She then moved on to biotech industry and joined Amgen in 2015 as Principal Scientist, Antibody Discovery Lead at Amgen China R&D Center. She has conducted extensive basic research in cancer and infectious diseases and led biologics drug early discovery throughout her career. She has 56 peer-reviewed publications and holds 7 issued patents or patent applications. Since she joined Amgen, she has been focused on developing innovative technologies for antibody discovery and established camelid single domain antibody platform and antibody phenotypic screening platform at Amgen.
|Iain Campuzano||Amgen Inc|
Principal Scientist, Discovery Attribute Sciences
Iain Campuzano works in and manages a core analytical research group within Amgen Research. He has invented/co-invented six mass spectrometry related patents and published over 50 peer reviewed articles and book chapters. He has also presented and organised/chaired sessions at multiple international conferences such as ASMS, ASMS Sanibel, PEGS, Discovery on Target and PITTCON.
|Sandra Garces||Amgen Inc|
Medical Director, Global Drug Developmentelopment
Sandra Garces is Rheumatologist with more than a decade of clinical experience, focused on the use of biologic therapies in the treatment of patients with chronic inflammatory diseases. She did her PhD in the Gulbenkian Institute of Science with a thesis entitled “Clinical Relevance of Drug Immunogenicity”. She developed an algorithm that uses information on drug concentrations and immunogenicity to help guide therapeutic decisions towards more cost-effective therapeutic strategies in clinical practice. In 2016 she joined Eli Lilly & Co. where she has worked on the assessment of the clinical relevance of IMG across different programs. She recently joined Amgen as a clinical research director in 2019.
|Mei Han||Amgen Inc|
Scientist, Pharmacokinetics & Drug Metabolism
Mei has worked in biotech industry for 20 years after she obtain her MS from Dept of Chemistry and Biochemistry, Montana State University. She is currently a Senior Scientist in the Pharmacokinetics & Drug Metabolism (PKDM) department at Amgen South San Francisco. Over the years, she has worked in different functional areas across Amgen including Analytical Sciences, Protein Sciences and PKDM. Her experience ranging from chromatographic (such as SEC, CEX, HIC and RP-HPLC), electrophoresis (cIEF, CE-SDS, CE-MS) and mass spectrometry analytical method development, inter- and intra- departmental method transfer such as from Analytical Sciences to QC labs, involved in IND and BLA filing; she is also experienced in small and middle scale protein purification. She implemented Capillary Electrophoresis (CE) techniques into Protein Science and PKDM departments, developed an automated immunoaffinity capture (IA)-CE-MS intact mass analysis biotransformation workflow in PKDM department to support multiple pipeline projects ranging from antibodies, fusion proteins and antibody conjugates in vitro and in vivo as well as other characterization techniques. Currently she leads the large molecule ADME team within PKDM, interacting with Project Team Representatives to support projects and serve as resource for protein characterization, analytical method development, troubleshooting and experiment planning.
|Fides Lay, PhD||Amgen Inc|
Scientist, Cell Line Developmentelopment & Genetic Characterization
Fides Lay received her Ph.D. in Genetics, Molecular and Cellular Biology from the Keck School of Medicine at University of Southern California in 2014 after completing a thesis on the epigenetic regulation of tumorigenesis. She went on to complete a postdoctoral fellowship at the University of California, Los Angeles where she developed and implemented high-throughput sequencing-based assays as well as genetic editing tools to study the mechanism of normal and malignant blood development. Fides joined Amgen’s Cell Line Development and Genetic Characterization team in 2018. She is interested in developing better methods to generate and characterize cell lines for multiple biotherapeutics modalities.
|Christy Thomson||Amgen Inc|
Christy Thomson received her PhD in Biochemistry from McMaster University where her research focused on protein structure and function. Her post-doctoral research at the University of British Columbia examined the human antibody response to common pathogens such as HCMV and H1N1. Since joining Amgen in 2012, her focus has been biologic discovery. Dr. Thomson is leader of the Antibody Characterization and Discovery Team which brings together diverse expertise and strategies aimed at early identification of B cells specific to target and the development of assays and reagents to differentiate lead antibodies meeting design goals.
|Xinchao Yu, PhD||Amgen Inc|
Senior Scientist, ImmunoOncology & Molecular Engineering
Dr. Xinchao Yu is a senior scientist and cryo-EM lab head at Amgen South San Francisco. Xinchao received his Ph.D. in Biophysics from Boston University with comprehensive training in single particle cryo-EM. During his postdoctoral career at the Memorial Sloan-Kettering Cancer Center, he used a combination of X-ray crystallography and cryo-EM to study molecular machineries involved in membrane trafficking processes, as well as honing his expertise in membrane protein expression and purification. With a passion to pursue innovative medicine to help patients, Xinchao joined Amen in 2015 to lead the cryo-EM initiative to set up the cryo-EM infrastructure to support drug discovery. Through extensive cross-functional and cross-sites collaborations, Xinchao and the cryo-EM team have made significant progress to support a number of important research pipelines, including several challenging membrane protein targets.
|Shou-Ching Jaminet||Angiex Inc|
Founder & Head of Research
Shou-Ching Jaminet, Ph.D., is Founder and Head of Research at Angiex, Inc. Shou-Ching is a molecular and vascular biologist, a leading expert on gene expression profiling and TM4SF1 biology, and discoverer of TM4SF1’s roles in endothelial cell biology. At Angiex, Shou-Ching has led creation of an antibody-drug conjugate for solid tumors that is in preclinical development. Before founding Angiex, Shou-Ching was Director of the Laboratory of Multi-Gene Transcriptional Profiling at Beth Israel Deaconess Medical Center. She identified TM4SF1 as a new endothelial cell biomarker; elucidated the role of TM4SF1 in blood vessel formation; demonstrated that TM4SF1 is essential for endothelial cell movement and proliferation; discovered a novel internalization route along microtubules to the nucleus; and discovered novel mechanisms of intercellular interaction mediated by TM4SF1-rich nanopodia that may play an important role in metastasis.
|Janice Reichert, PhD||Antibody Society|
Janice M. Reichert, PhD, is Executive Director of The Antibody Society. She is also the founder and Editor-in-Chief of mAbs, a peer-reviewed, PubMed-indexed biomedical journal that focuses on topics relevant to antibody research and development, and co-editor of the Handbook of Therapeutic Antibodies. She has published extensively on development trends for antibody therapeutics, and she has presented her research results as an invited speaker at conferences held worldwide. Dr. Reichert received her PhD in Chemistry from the University of Pennsylvania and did her post-doctoral training at Harvard Medical School.
|Mahendra Deonarain, PhD||Antikor Biopharma Ltd|
Chief Executive and Science Officer
Dr Deonarain studied at Imperial College and Cambridge University where he carried out PhD research into protein engineering. From 1997-2011 Dr Deonarain was a Principle Investigator at Imperial College in Antibody Technology, which led to some novel technologies being developed commercially. Dr Deonarain now retains an honorary position. He has published over 80 papers and patents in protein/antibody engineering/conjugates. In 2014, he co-founded Antikor Biopharma where he is the CEO leading a team to develop the next-generation of antibody-fragment based ADCs.
|Oliver Hill, PhD||Apogenix AG|
Vice President Molecular Biology
Oliver Hill joined Apogenix in March 2006. He is an expert for protein engineering and expression. Prior to his position at Apogenix, he headed the protein expression and purification group at Graffinity Pharmaceutical Design GmbH (Heidelberg, Germany) from 1999 to 2006. At Graffinity Oliver Hill was responsible for delivering a broad spectrum of target proteins for screening on a chemical microarray platform. His work in former, academic R&D positions at the Lower Saxony Institute for Peptide Research (Hannover, Germany; 1992-1996) and the Institute for Molecular Biotechnology (Jena, Germany; 1997-1998) included gene hunting, protein engineering and the development of recombinant phage display technologies. Mr Hill studied biology at the University of Hannover where he also received his Ph.D. from the Department of Chemistry in 1997.
|Philipp Spycher, PhD||Araris Biotech AG|
Philipp completed his undergraduate studies at the University of Basel (Switzerland) in Nanoscience, graduate studies at ETH Zurich (Switzerland) in Biomedical Engineering and PhD studies in materials and protein engineering at ETH Zurich. Three years post-doc at Prof. Roger Schibli’s lab at PSI Villigen (Switzerland) focused on antibody-drug conjugates followed by being a PSI Founder Fellow for two years at PSI Villigen that resulted in the incorporation of Araris Biotech AG in January 2019 and since June 2019 CEO of Araris.
|Bas van der Woning||argenx BVBA|
PhD in cell biology. 10 years’ experience in antibody engineering. Was responsible for pre-clinical development of ARGX-115, targeting GARP-TGFβ1, for immuno-oncology, until AbbVie took over for clinical development. Lead scientist TGFβ-related projects and project leader on the ARGX-118 project for severe asthma.
|Joshua LaBaer, MD, PhD||Arizona State University|
Executive Director & Professor, Molecular Sciences
Joshua LaBaer is one of the nation’s foremost investigators in the rapidly expanding field of personalized diagnostics. His efforts focus on the discovery and validation of biomarkers — unique molecular fingerprints of disease — which can provide early warning for those at risk of major illnesses, including cancer and diabetes. Formerly founder and director of the Harvard Institute of Proteomics, LaBaer was recruited to ASU’s Biodesign Institute as the first Piper Chair in Personalized Medicine in 2009. The Virginia G. Piper Center for Personalized Diagnostics (VGPCPD) has a highly multidisciplinary staff of molecular biologists, cell biologists, biochemists, software engineers, database specialists, bioinformaticists, biostatisticians, and automation engineers. VGPCPD applies open reading frame clones to the high throughput (HT) study of protein function. In addition, his group invented a novel protein microarray technology, Nucleic Acid Programmable Protein Array, which has been used widely for biomedical research, including the recent discovery of a panel of 28 autoantibody biomarkers that may aid the early diagnosis of breast cancer. LaBaer earned his medical degree and a doctorate in biochemistry and biophysics, from the University of California, San Francisco. He completed his medical residency at the Brigham and Women’s Hospital and a clinical fellowship in oncology at the Dana-Farber Cancer Institute, both in Boston. He has contributed more than 150 original research publications, reviews and chapters. LaBaer is an associate editor of the Journal of Proteome Research, a recent member of the National Cancer Institute’s Board of Scientific Advisors, Chair of the Early Detection Research Network Steering Committee and recent president of the U.S. Human Proteome Organization.
|Jen Fox, PhD||AstraZeneca|
Scientist, Bioassay, Impurities and Quality, Analytical Sciences
No Bio Available
|Saleha Patel, PhD||AstraZeneca|
Senior Research Scientist, Protein Science & Discovery Biology
Since joining AstraZeneca in 2017, Saleha has worked on and produced high quality protein reagents for a number of early discovery projects. Her specific focus within the team is in the area of protein QC and sample preparation for specialist downstream applications. More recently, she has been developing and prosecuting biochemical assay strategies for screening and hit dicovery. Prior to joining AstraZeneca, Saleha studied Biochemistry at the University of York, followed by an MSc in Bioscience Technology with a short time also spent at CRUK at the London Research Institute. She completed her PhD and first Postdoc at the University of Leicester in partnership with UCB Pharma. Her work looked into characterising the structures and function of antagonists of the Wnt signalling pathway using NMR, EM and several other biophysical techniques.
|Amit Kumar||AstraZeneca Biologics|
Scientist I, ADPE
Amit Kumar received his PhD in Chemistry from the University of Houston. He then pursued postdoctoral work at University of Texas southwestern Medical Center where he worked on design and synthesis of molecular imaging probes and therapeutic agents for various diseases. He joined AstraZeneca in 2016 and is currently working on antibody-drug conjugates and novel conjugation modalities for oncology applications.
|Sarav Rajan||AstraZeneca Biologics|
Sarav Rajan obtained his PhD from McGill University and a post-doctoral fellowship from the University of Toronto, specializing in the use of phage display to isolate therapeutic antibodies. He has been at AstraZeneca in the department of Antibody Discovery and Protein Engineering for over 7 years where he has earned several distinctions, including company-wide innovation awards. He currently manages a team in Maryland that has pioneered a novel discovery platform that captures and screens the natively-paired antibody repertoire from millions of B cells.
|Masha Fridkis-Hareli||ATR LLC|
Founder & President
Masha Fridkis-Hareli, MSc, PhD, is an immunologist, consultant and inventor with over 20 years of experience in academia and industry. She is a Founder and President of ATR, LLC, a translational research company providing scientific consulting and laboratory services in immunoassay development to research institutions and the biotechnology industry. During her post-doctoral training at Harvard University, she designed and developed a group of novel compounds for treatment of autoimmune diseases. After serving as Principal Investigator at the Dana-Farber Cancer Institute, Dr. Fridkis-Hareli transitioned to industry where she held a variety of positions with increasing responsibilities at Resolvyx Pharmaceuticals, Charles River Laboratories, Taligen Therapeutics and Alexion Pharmaceuticals. Dr. Fridkis-Hareli is a co-author of over 100 publications and 17 issued patents. She is an adjunct professor at the Harvard Extension School, Northeastern University, Worcester Polytechnic Institute and Framingham State University, where she teaches biotechnology and immunology courses at the graduate biotechnology programs.
|Claes Gustafsson, PhD||ATUM|
As ATUM’s Co-Founder and CCO, Dr. Gustafsson oversees most of the company's external communications. Prior to co-founding ATUM, Dr. Gustafsson led, managed and collaborated with key strategic teams at Maxygen Inc. Before Maxygen, Dr. Gustafsson worked as a scientist at Kosan Biosciences, a number of research, teaching, and post-doctoral positions at UCs Santa Cruz and San Francisco, and at University of Umeå. He received his Ph.D. in Molecular Biology/Biochemistry from the University of Umeå, Sweden.
|Peter Hudson||Avipep Pty Ltd|
CSO & Chief Scientist
Dr Peter Hudson, FTSE, BSc Hons (Adelaide, Australia), PhD (MRC-LMB, Cambridge, UK). Peter is CSO of Avipep P/L (Melbourne) and Avipep Therapeutics P/L (Boston) and recently led a large oncology consortium to complete the first Phase 1 clinical trial of a novel engineered antibody (AvibodyTM) targeting prostate and ovarian cancer. Peter has co-founded four Australian biotech companies Evogenix Pty Ltd (2001), Avipep Pty Ltd (2005), CarTherics Pty Ltd (2015) and IsoClide Med Pty Ltd (2017). Peter is currently an Adjunct Professor at the University of Queensland and was formerly a Chief Research Scientist and Program leader in CSIRO (1990-2008) and Deputy CEO and Scientific Director of the CRC for Diagnostics (1995-2007). He was also Director for Business Development in the AIBL Alzheimer’s Disease consortium and the CRC for Mental Health (2009-2012). Peter was elected to the Australian ATSE Academy and has been awarded the AMRAD Biotechnology and CSIRO Chairman’s Medals.
|Gur Yaari||Bar Ilan University|
Gur Yaari is an Associate Professor in the Faculty of Engineering of Bar Ilan University, Israel. He received his BSc degree in physics and math, MSc in high energy physics, and PhD in interdisciplinary physics, all from HUJI. He was a postdoctoral fellow at Yale University. Yaari joined the faculty of Engineering in 2013. His current research interest focuses on the development of computational and statistical tools to process and analyze high-throughput biological data, with a special spotlight on the adaptive immune system.
|Pedro Paz||Bayer HealthCare Pharmaceuticals|
Senior Staff Scientist, Molecular & Cellular Immunology Biologics Research
Pedro E. Paz, PhD heads the Immunoprofiling Group in Biologics Research at Bayer Pharmaceuticals. He received both undergraduate and graduate degrees in Molecular Cell Biology- Immunology from University of California - Berkeley. He is responsible for the immunogenicity assessment of biotherapeutics in the drug development pipeline.
|Maksim Max Mamonkin||Baylor College of Medicine|
Assistant Professor Pathology & Immunology, Center for Cell & Gene Therapy
Dr Mamonkin is a faculty member at the Center for Cell and Gene Therapy at Baylor College of Medicine. The primary focus of his laboratory is development of novel therapeutic platforms for patients with difficult-to-treat hematologic malignancies and alloimmune complications.
|Norihiro Watanabe||Baylor College of Medicine|
PostDoc Associate, Gene Therapy Center
Dr. Watanabe is an Instructor at the Center for Cell and Gene Therapy, Baylor College of Medicine with a long-standing interest in the development of novel immunotherapeutic strategies. His research areas include developing T cell-based approaches for the treatment of both hematological malignancies and solid tumors. Since joining CAGT, he has been focusing on optimizing genetic engineering strategies to maximize the potency of tumor-targeting T cells and developing novel T cell-based therapeutic platforms.
|Sheila Magil, PhD||BDO USA LLP|
Managing Director, Industry Special Services
Sheila Magil has over 20 years of experience in quality and analytical method development for biologics, peptides and small molecules. Her expertise includes quality assurance, protein and peptide biochemistry and analytical development. She was formerly Senior Manager of Analytical Development and Quality Control at Biomeasure, Inc., and previously held positions at Waratah Pharma, Alkermes, Bion and HHMI at Massachusetts General Hospital. Dr. Magil has implemented quality systems and has managed external analytical and QC activities for multiple biopharmaceutical products. Dr. Magil holds a PhD in Biochemistry from the University of Minnesota.
|Frank Riske, PhD||BDO USA LLP|
Managing Director, Bioprocess Technology Group
Frank J Riske, Ph.D., has over 30 years of experience in the biopharmaceutical industry and has been involved in the development, or improvement, of eight commercial protein products. Prior to joining BPTC four years ago (and more recently the BioProcess Technology Group at BDO; after BPTC acquisition), Dr. Riske was a Senior Director in the Late Phase Process Development Group at Genzyme, a Sanofi company. At Genzyme, Dr. Riske was responsible for the development of late stage downstream processes for recombinant enzymes, monoclonal antibodies, Adenovirus (gene therapy) and the identification and exploration of new technologies, including continuous processing, to streamline and improve purification. Prior to joining Genzyme, Dr. Riske managed the development, implementation and manufacture of a peptide bound within a novel sustained release vehicle, and the development of a next generation process to purify IVIG from plasma (both at Epic Therapeutics). Before Epic, Dr. Riske held positions at Repligen and Hoffmann-LaRoche during which he developed and improved, downstream processes for proteins produced in mammalian cell culture, E coli, and Pichia systems. Dr. Riske was also responsible for the manufacture of MAb fragments at Repligen. Dr. Riske has published over twenty peer reviewed papers and patents and is active in the scientific community as both a mentor to young scientists and as a conference speaker and organizer. Dr. Riske received his B.S. in Biology from Fairfield University, Ph.D. in Biochemistry and Microbiology from Rutgers University and completed a post-doctoral position at Hoffmann-LaRoche.
|Brenda Laster||Ben Gurion University of the Negev|
Associate Professor Nuclear Engineering & Director, Jerry J Cohen Radiobiology Lab
Professor Laster received her B.S. in biology from Stern College for Women, New York, NY and her graduate studies were carried out at Memorial/Sloan Kettering, New York NY, where her major was Diagnostic Cytology. Her Ph.D. studies in experimental pathology and radiation biology were carried out at the State University of New York at Stony Brook, Stony Brook, NY and the Union Institute, Cincinnati, Ohio. Her thesis was on “Binary Systems for the Improvement of Cancer Radiotherapy” and her thesis advisor was Victor P. Bond, M.D., Ph.D. Before joining the faculty of Ben Gurion University, Professor Laster was a scientist in the Medical Department of Brookhaven National Laboratory in Upton, N.Y. and an Assistant Professor in the Department of Radiation Oncology in the School of Medicine at the State University of New York at Stony Brook. She served as a visiting professor in the Department of Radiation Physics at the University of Lund, Lund, Sweden, and in the Social Dimensions of Science, Project WISE, at the State University of New York at Stony Brook, Stony Brook, N.Y.
|Anupam Singhal, PhD||Berkeley Lights Inc|
Anupam Singhal earned his PhD from the University of British Columbia and has over 15 years of experience in nanotechnology and microfluidics at UBC, the University of Toronto and Stanford University. His work has been cited over 600 times and resulted in several patents for molecular disease diagnosis, antibody discovery, and development of production cell-lines for biologics . At Berkeley Lights, Anupam leads the development of next-generation platforms for the discovery and development of antibody therapeutics.
|Corinna Fiorotti, PhD||BioAgilytix|
Corinna Fiorotti obtained her Ph.D. in Microbiology and Immunology from the University of New Hampshire before attending Harvard Medical School. Since, she has served as a faculty member at Harvard and has held scientific leadership positions at Eyetech and Pfizer where she focused on developing cell-based assays for the detection of neutralizing antibodies, ADA, and PK assays. She joined BioAgilytix in 2015 as a Business Development Director and was promoted to Scientific Officer in 2019.
|Jim McNally, PhD||BioAgilytix|
Dr. McNally has an extensive background in bioanalytical assay development and program leadership spanning nearly 20 years working in the pharmaceutical and biotechnology industry. Prior to joining BioAgilytix, Dr. McNally was Executive Director at CRISPR Therapeutics, where he lead a team of scientists to develop a portfolio of assays to support development of gene-based therapeutic candidates throughout their lifecycle. He has also previously held roles at Genzyme, Pfizer, EMD Serono, and Shire which have given him broad experience in the development of large molecule, gene therapy, and cell therapy biotherapeutics. Dr. McNally is a recognized thought leader in the development and application of bioanalytical methods used in regulatory submissions and is specifically skilled in progression of biotherapeutics from research through clinical development. He has a special interest in the immunogenicity of biotherapeutics and leads an industry-wide working group to address this issue. A key part of his role at BioAgilytix is advising on emerging scientific developments and providing scientific and regulatory guidance. Dr. McNally obtained his B.S. in Biology from Mississippi State University, his PhD Viral Immunology from Louisiana State University School of Medicine in Shreveport, and his Post-Doc in Viral Immunology from University of Massachusetts Medical School.
|Jennifer Chadwich, PhD||BioAnalytix, Inc.|
Vice President, Biologic Development
Dr. Jennifer Chadwick is an innovative leader with >15 years professional academic and industrial experience in biotechnology, pharmaceutics and life sciences. She is Vice President of Biologic Development at BioAnalytix and formerly tenured Professor and Louise Byrd Graduate Educator in the Department of Pharmaceutical Chemistry at the University of Kansas. Prof. Chadwick transitioned to industry after founding a company to commercialize technology developed in her academic lab and serving as CSO and Director. She is a recognized expert in analytical development, formulation and stability assessment of biologics and has extensive background in biologic drug discovery, translational research and early/late stage development of complex, emerging therapeutics applied to diverse clinical indications. Her corporate responsibilities have included corporate/scientific enterprise strategy, product development, business development, project management, team building and alliance management, IP portfolio management and early-stage fundraising. Dr. Chadwick has a significant history and ongoing commitment of influential leadership in professional communities and strong engagement in mentoring and career development. She serves as Associate Director, CASSS; Visiting Scholar, Department of Chemistry and Chemical Biology, Northeastern University; Editorial Advisory Board member, Journal of Pharmaceutical Sciences and Scientific Reports; MassBio Steering Committee for Academic-Industry Relations; Mentor for MassCONNECT; and Co-chair of Mentors, Advisors, Peers and Sponsorship, WIB, Boston Chapter.
|Thomas Little, PhD||Bioassay Sciences, Thomas A Little Consulting|
President and CEO
Dr. Little is President of BioAssay Sciences (BAS) a globally recognized bioassay consulting company for biologicals and vaccines. BAS specializes in the design, calculation and control of potency and relative potency for bioassays. BAS specializes in In-Vivo and In-Vitro bioassays. BAS works with international companies and health authorities globally to achieve product development goals aligned to ICH and USP guidance. BAS is a strategic partner of SAS/JMP and a division of Thomas A. Little Consulting. Dr. Little has developed specific content courses in statistical methods and data analysis, Bioassay Design and Validation, Quality Risk Management, design of experiments, Robust Optimization, Design Space and Tolerance Design, Assay Development and Method Validation, statistical process control, mixture design of experiments, Stability Analysis and Nonlinear Modeling. These courses are used by a variety of fortune 100+ companies to train their chemists, engineers and scientists.
Head, Bioassay Department
PhD. Head of Bioassay Department at Biocad, Russian Leading Innovative Biotechnology Company. The department is responsible for selection the bioassay strategies and development, validation and transfer bioassays including potency assays in support of drug development pipeline.
|Qingcong Lin||Biocytogen Boston Corp.|
|Amr Ali, PhD||Biogen|
Amr Ali’s research focuses on leveraging multi-omics techniques to improve bioprocesses as well as developing new analytical methods for characterization of complex therapeutic proteins. He has been at Biogen for 9 years and had many roles throughout his tenure there ranging from raw material analysis, cell culture development and protein characterization. Amr Ali has a PhD in analytical chemistry from Northeastern University as well as a master’s degree in bioinformatics and a bachelor’s in biomedical engineering from Boston University.
Scientist, Analytical Developmentelopment
George has a BS in chemistry and a PhD in Biochemistry. His graduate studies under Prof. Alan Marshall at Florida State University focused on development and optimization of hydrogen/deuterium exchange mass spectrometry to study protein-protein interactions. Shortly after he graduated, he joined the technical development group at Biogen in 2011 where his job responsibilities focus on the biophysical characterization of proteins and gene therapy products.
|Melissa Geddie, PhD||Biogen|
Senior Scientist, Antibody Discovery
No bio available
Scientist I, Antibody Discovery
Christina has been a core member of the Antibody Discovery team within Biologics Drug Discovery for over 10 years. She graduated from MIT with a BA in Chemical Engineering and a MA in Bioengineering from the University of Pennsylvania. She has extensive experience working with phage and yeast display systems, including the Dyax and Adimab platforms. She has led numerous Antibody Discovery campaigns for a variety of targets, including therapeutic candidates for oncology, autoimmune disease, fibrosis, MS, and neurological indications.
Senior Scientist, Analytical Developmentelopment
I have been working at Biogen since early 2013, participated in the analytical assay development from both biological and chemical perspectives for protein pharmaceuticals as well as AAV-based gene therapeutics. Prior to the current role, I spent 5 years in industry optimizing nucleic acid-based diagnostic instruments and reagents for contagious and inherited diseases, after obtained my PhD degree in Biological Chemistry at the University of Michigan and completion of postdoctoral training at MIT and Brandeis University in the field of molecular and cell biology.
|Yizhou Zhou, PhD||Biogen|
Scientist II, Cell Culture Developmentelopment
Yizhou Zhou is a Scientist in Protein Development of Biogen. She leads vector design, genetic characterization, and multi-omics analysis to support cell line and cell culture process development. She obtained her Ph.D. in Molecular Biology at the University of Michigan, and worked at Genentech before joining Biogen.
|Johanna Abend||BioMarin Pharmaceutical Inc|
Senior Scientist, Immunogenicity Assessment
Johanna Abend received her Ph.D. in Microbiology and Immunology from the University of Michigan, Ann Arbor in 2008, where the focus of her research was aimed at investigating cytokine-mediated regulation of the human polyomavirus BKV. She continued her training in virus-host interactions with a post-doctoral fellowship at the NCI/NIH in Bethesda, MD where she investigated cellular targets of Kaposi’s sarcoma-associated herpesvirus (KSHV) microRNAs, with a particular interest in immune-related targets (TWEAKR and IRAK1). Following her post-doctoral training, she worked at the Novartis Institutes for BioMedical Research (NIBR) in Emeryville, CA as an investigator and Project Team Leader for multiple antiviral drug discovery teams targeting polyomaviruses and Hepatitis B virus (HBV) using both biologics and small molecule modalities. After seven years at Novartis, Johanna joined BioMarin in January of 2019 as a Senior Scientist in Immunogenicity Assessment where she has supported the filing of a supplemental BLA for Palynziq, a PEGylated enzyme substitution therapy for the treatment of PKU. Johanna has over 8 years of industry experience in antiviral drug development and immunology.
|Brian Long||BioMarin Pharmaceutical Inc|
Associate Director & Senior Scientist II, Translational Sciences & Immunogenicity Assessment
Brian Long received his Ph.D. in Microbiology and Immunology from The University of North Carolina, Chapel Hill in 2004 and pursued post-doctoral training at The Gladstone Institutes and the University of California, San Francisco where he investigated the role of innate immunity in HIV disease pathogenesis. Following his post-doctoral training, he continued as a Research Scientist in the Division of Experimental Medicine at UCSF where he worked on the development and standardization of humanized mouse models for the evaluation of HIV immunology, therapeutics and drug discovery. Brian joined BioMarin in June of 2014 and is currently an Associate Director in Translational Sciences and Immunogenicity Assessment where he provides immunologic expertise to drug programs across developmental stages and develops immunogenicity and safety strategies for novel biologic therapeutics. Brian has over 20 years of experience in immunology and infectious disease, autoimmunity, cell signaling, cancer biology and drug development.
|Eugene Zhukovsky, PhD||Biomunex Pharmaceuticals|
Dr. Zhukovsky has over two decades of professional experience in the field of biotherapeutics research and development. He currently applies optimized monospecific and novel bispecific antibody platforms to the development of immunotherapeutics for cancer, with a particular focus on leveraging the biology of immune checkpoint modulators. Currently, Dr. Zhukovsky is the CSO of Biomunex Pharmaceuticals, and he also consults with other biotechnology companies. Previously, he served as the CSO of Affimed Therapeutics; there he was responsible for the advancement of candidate therapeutics from discovery to the clinic, and novel technology development. Prior to that he was a Senior Research Fellow in the Biotherapeutics Department at Boehringer Ingelheim Pharmaceuticals, Inc. leading antibody discovery efforts in the therapeutic areas of inflammatory and cardiovascular diseases. Prior to that Dr. Zhukovsky was an Associate Director at Xencor, Inc. where he led translational research efforts resulting in several therapeutic candidates targeting malignant B cells. One of these therapeutic antibodies is currently undergoing late-stage clinical trials. Dr. Zhukovsky began his professional career employing phage display technology at Neurex Corporation. He then moved to Lynx Therapeutics (now Illumina, Inc.) to work on the development of genomics technologies before returning to protein/antibody engineering and biotherapeutics development at Xencor, Inc. Dr. Zhukovsky performed a postdoctoral fellowship at Genentech, Inc. He received a PhD in biochemistry from Brandeis University and an MS degree in bioorganic chemistry at St. Petersburg's State University.
|Alexander Muik||BioNTech AG|
No Bio available
|Eric Alonzo||bluebird bio|
Senior Scientist, Cell Analytics
Dr. Alonzo currently leads the Immuno-oncology characterization and analytics team in the Process and Analytical Development Department at bluebird bio. His research focuses on development of analytical and characterization assays for the CARs T/TCR cell program. Prior to bluebird bio, Dr. Alonzo led efforts developing T cell-based therapies at Agenus (Lexington, MA), and previous to his work at Agenus, he was a postdoctoral fellow at Massachusetts General Hospital/Harvard Medical School where he worked on a mouse model of T cell acute lymphoblastic leukemia. Dr. Alonzo received his PhD from the Cancer Biology Program at the Memorial Sloan-Kettering Cancer Center.
|Alden Ladd||bluebird bio|
Senior Associate Scientist, Cellular Therapy Mfg & Process Development
Alden Ladd is a scientist II at bluebird bio (Cambridge MA) where he has been employed for six years. During his time at bluebird he has participated in the process development and technology transfer of all of bluebird’s internal oncology programs. Alden is a subject matter expert in cellular process development and scale up, and is currently leading the technology transfer of bluebird bio’s first TCR based therapy for MAGE-A4 positive solid tumors. Alden is also leading in vivo efforts to understand surrogate biomarkers of potency for CAR and TCR based products. Alden holds a degree in biochemistry from Northeastern University.
|Ingo Gorr, PhD||Boehringer Ingelheim Pharma GmbH & Co KG|
Director & Head
Ingo Gorr received his Biology degree from the University of Wuerzburg in Germany, followed by a PhD in the Molecular Cell Biology department at the Max-Planck-Institute of Biochemistry in Martinsried/Germany. He then joined Roche first in Basel then in Penzberg and since 2015 he is leading the Early Stage Bioprocess Development (USP&DSP) at Boehringer Ingelheim in Biberach/Germany.
|Linzhi Chen, PhD||Boehringer Ingelheim Pharmaceuticals Inc|
Senior Research Fellow & Group Leader
Dr. Chen obtained his PhD degree in organic chemistry from the University of Mons, Belgium. After postdoctoral training, he joined 3M Pharmaceuticals and then Boehringer Ingelheim Pharmaceuticals and has worked primarily on metabolite profiling/ID and bioanalysis in support of small molecule drug development. In recent years at Boehringer Ingelheim, he has led a group to provide LC/MS-based bioanalytical support to biotherapeutic development programs, and developed a number of LC/MS assays for quantitation of various biotherapeutic proteins such as nanobodies, Fabs, bispecifics, mAbs, etc. His group also developed immunocapture-LC/MS methodology for simultaneous ADA isotyping and semi-quantitation. His recent research focuses on LC/MS determination of in vivo biomodifications of biotherapeutics and their impact on PK/PD. Dr. Chen has more than 30 publications in peer-reviewed journals.
|Andrew Nixon, PhD||Boehringer Ingelheim Pharmaceuticals Inc|
Vice President Biotherapeutics Molecule Discovery
Dr. Nixon currently is Vice President of Biotherapeutics Molecule Discovery at Boehringer Ingelheim. In this role, he is responsible for early biologic discovery activities. Prior to joining Boehringer Ingelheim, Andy spent 17 years at Dyax including four years as Head of Research and most recently was at Magenta Therapeutics a stem cell transplant company. At Dyax, he focused on biologic drug discovery including peptides, small proteins and antibodies across multiple therapeutic areas including oncology and inflammation. He was a key scientific partner for Dyax’s Licensing and Funded Research Program (LFRP), contributed to numerous antibodies in clinical studies including Avelumab, an anti-PD-L1 antibody and Opicinumab, an anti-Lingo-1 antibody and led from discovery to IND Takhzyro, a plasma kallikrein inhibitory antibody that was approved in 2018.
|Bonnie Rup, PhD||Bonnie Rup Consulting LLC|
Bonita Rup is a biopharmaceutical development consultant, providing expert advice on bioanalysis, immunogenicity risk assessment, and related regulatory strategy aspects of biopharmaceutical development. Previously she was Research Fellow and lead for the Immunogenicity Discipline at Pfizer, Assistant Vice President of Protein Bioanalytics in Wyeth, and held various positions directing development and application of immuno-ligand binding assay technologies for PK, immunogenicity and protein impurity analysis, and other aspects of biopharmaceutical development. During her career, she has been involved in multiple regulatory filings during preclinical, clinical development and marketing approval of biopharmaceutical products. She has been a member of AAPS, EIP, European IMI ABIRISK consortium, and Biosafe; with these organizations, she has been a co-author for multiple publications related to monitoring immunogenicity and bioanalysis of therapeutic proteins. Bonnie received her B.S. from University of Massachusetts, Amherst, Ph.D. from University of Texas, Austin, and conducted postdoctoral research at Duke University and University of Rochester, NY.
|Robert Giugliano||Brigham & Womens Hospital|
Physician, Cardiovascular Medicine
Dr. Giugliano, MD is a Senior Investigator with the TIMI Study Group, Staff Physician in the Cardiovascular Division at Brigham and Women’s Hospital, and Professor of Medicine at Harvard Medical School.
He graduated Summa Cum Laude, Phi Beta Kappa (Mathematics) from Dartmouth College (1985), receiving a medical degree at Harvard Medical School (1989). Dr. Giugliano completed residency and chief residency at Cedars-Sinai Medical Center (UCLA affiiliate,1989-93) and cardiology fellowship at Massachusetts General Hospital (1993-6).
In 1996, Dr. Giugliano joined the Brigham and Women’s Hospital as a Medicine Research Fellow in the Thrombolysis in Myocardial Infarction (TIMI) Study Group directed by Eugene Braunwald, and completed a Science Masters (Epidemiology) at the Harvard School of Public Health. In 1997, he joined the Cardiovascular Division faculty of the Brigham and Women’s Hospital and has served as the principal investigator for 9 multicenter clinical trials at TIMI.
His areas of research interests include novel antithrombotic, fibrinolytic agents, and lipid-lowering therapies, and patient outcomes following Acute Coronary Syndromes (ACS). He has authored more than 400 articles and chapters, and delivered hundreds of lectures. Dr. Giugliano is the Principal Investigator for the VESALIUS-CV trial of the PCSK9 inhibitor evolocumab in patients at high risk for cardiovascular events with no prior MI or stroke, and also the ENGAGE-AF TIMI 48 trial of the factor Xa inhibitor edoxaban in 21,105 patients with fibrillation. He is also a member of the Operations Committees and Lead TIMI Investigator for the FOURIER trial studying evolocumab in 27,564 hyperlipidemic patients with prior cardiovascular disease; the IMPROVE-IT trial evaluating ezetimibe in 18,144 patients post ACS; and the EARLY ACS trial of eptifibatide in 9492 patients with ACS.
Dr. Giugliano serves on numerous Data Safety Monitoring Boards, clinical endpoint committees, and Holter/ECG Core Laboratories. He actively participates in the clinical activities of the Cardiovascular Division, attending in the Levine Cardiac Intensive Care Unit, telemetry unit, and consult services, and sees patients in a busy growing outpatient practice.
|Khalid Shah||Brigham & Womens Hospital|
Associate Professor of Neurosurgery & Director, Center for Stem Cell Therapeutics & Imaging
No bio available
|Julia Ding||Bristol Myers Squibb Co|
Director, Process Developmentelopment Analytical & Analytical Developmentelopment
Julia Ding is a director of process analytics and analytical development at Bristol Myers Squibb Devens site. She is leading a diverse and dynamic team responsible for enabling analytics for bioprocess development and characterization, analytical development and assay development in advancing CMC control strategy and developing new technologies , such as PAT for next generation biologic process. Julia Ding also serves in BMS biologic specification committee and comparability council.Prior to joining Bristol Myers Squibb, Julia Ding was a manager at PPD leading a multifunctional analytical development team in quality control testing, assay development, assay validation, assay life cycle management, and product characterization. Julia obtained her Ph.D. in physical organic chemistry from Emory University and postdoc from University of California at Berkeley.
|Daron Forman||Bristol Myers Squibb Co|
Daron Forman is currently a Principle Scientist within the Discovery Biotherapeutics Department of Bristol Myers Squibb. For the last 10 years he has helped to setup an immunogenicity risk assessment core group which utilizes in silico, in vitro and in vivo tools to help select lead drug candidates for further development. He earned dual Bachelor of Arts degrees in Biology and Psychology at the University of Rochester and then joined the lab of Dr. Aldo Rossini at the University of Massachusetts Medical School for his PhD work investigating the effects of viral infection on stem cell transplantation tolerance. After completing his PhD in Immunology and Virology, he joined the lab of Dr. John Iacomini at Harvard University for his post-doctoral work examining mechanisms by which T cells are rendered tolerant in mice reconstituted with retrovirally transduced bone marrow. Prior to BMS, Daron worked at Tolerx trying to understand the mechanisms of action of humanized anti-CD3 and anti-GITR monoclonal antibodies, as well as work on identifying biomarkers for both programs.
|Jochem Gokemeijer||Bristol Myers Squibb Co|
Associate Director Preclinical Discovery & Development
Jochem has been at Bristol-Myers Squibb for 14 years in different roles of responsibility focused on biologics drug development. For the last 8 years he has been focused on building a group for pre-clinical immunogenicity risk assessment and mitigation. He received his training at the University of Groningen and the Dana Farber Cancer Institute.
|Hao Jiang||Bristol Myers Squibb Co|
Senior Research Investigator II
Hao is currently a Principal Scientist at Bristol-Myers Squibb, who has worked at BMS for 13 year after 4-years postdoc training at University of Pennsylvania School of Medicine. He is working as a bioanalytical project lead outsourcing both small molecule and biologics projects in multiple disease areas. Hao has also taken the role as a technical lead for in-house assay development in several bioanalytical areas such as protein bioanalysis by LC-MS and PK/ADA bioanalysis on different assay platforms. He has presented his research work in many scientific conferences and published about 50 peer-reviewed papers. He is now the active members of several academic societies such as AAPS and ASMS.
|Julie Linhui Su||Bristol Myers Squibb Co|
Senior Research Investigator II
Julie received her bachelor’s degree in chemistry with concentration in biochemistry from Duke University. She did her graduate work with Anna Marie Pyle at Columbia University, focusing on the folding of large catalytic RNAs. She then moved to Boston and carried out postdoctoral work in Susan Lindquist’s lab at Whitehead Institute, using yeast as a model for characterizing the disruption of cellular pathways caused by misfolding of alpha synuclein. She joined Bristol Myers Squibb in 2009 and works in discovery, utilizing in vitro selection methods to identify biologic leads for therapeutic targets.
|Ming Zeng||Bristol Myers Squibb Co|
Dr. Ming Zeng is currently working at Bristol Myers Squibb Company leading biologics drug product development analytics teams. Ming received her PhD in Organic/Natural Product Chemistry from Univ of Maryland where her research focus was to develop the first generation of ADCs. She has more than 15 years of extended biologics characterization and method development experience. She was one of the primary authors for Opdivo® and Empliciti® BLA analytical sections.
|Wafik El-Deiry, MD, PhD, FACP||Brown University|
Professor, Pathology & Lab Medicine
Wafik El-Deiry, MD, PhD, FACP is Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is a Professor of Pathology and Laboratory Medicine, Professor of Medical Science, and Mencoff Family University Professor at Brown. He previously served as Deputy Director for Translational Research, co-Leader of the Molecular Therapeutics Program, Professor of Oncology, and the William Wikoff Smith Endowed Chair in Cancer Research at Fox Chase Cancer Center. From 2010 through 2014, Dr. El-Deiry was the Rose Dunlap Professor of Medicine and Chief of Hematology-Oncology at Penn State. In 2009, El-Deiry became an American Cancer Society Research Professor. He earned MD/PhD degrees from University of Miami School of Medicine and completed internal medicine residency and medical oncology fellowship at the Johns Hopkins Hospital and the Johns Hopkins Oncology Center. El-Deiry has >400 peer-reviewed publications and 5 edited books. In 2019, his H-index is 111 and he has >66,000 citations in Google Scholar. A practicing Oncologist, his scientific expertise is in cell death, drug resistance in cancer and drug discovery and development. Dr. El-Deiry has trained many students and post-doctoral fellows, physician-scientists, and continues to mentor junior scientists and faculty in basic and translational cancer research.
|Travis Young||California Institute for Biomedical Research|
Vice President Biologics
Dr. Young is the Vice President of Biologics at Calibr, a division of Scripps Research, where he was a member of the founding principal investigators. He currently serves as the lead investigator on multiple bench-to-bedside antibody and cellular therapy-based programs. Dr. Young maintains a research group focused in the development of novel therapeutics at the interface between protein engineering and synthetic biology. This research spans multiple disease indications including cancer, autoimmune, metabolic disorders, and infectious disease. His work has been highly awarded and received support from the Wellcome Trust, NIH (National Cancer Institute), Department of Defense, Mesothelioma Research foundation, American Cancer Society, among others, in addition to receiving backing from major pharma groups which supports clinical translation of programs. His work has resulted in numerous publications and patents with ~2000 citations in the past 5 years. He received a BS in biochemistry from Boston College and a PhD in chemical biology from The Scripps Research Institute as an ARCS scholar. At Scripps, his work was foundational for the development of programs in the Calibr pipeline today, including a bispecific antibody for prostate cancer which will enter clinical trials next year. After receiving his PhD, he completed a postdoc at Harvard Medical School with an NIH fellowship, in the department of Biological Chemistry and Molecular Pharmacology.
|Anne Skaja Robinson, PhD||Carnegie Mellon University|
Professor & Head, Chemical Engineering
Anne Skaja Robinson became Head of Carnegie Mellon University’s Department of Chemical Engineering in 2018. Prior to that, she she served as Chair of Chemical and Biomolecular Engineering at Tulane University for six years, and formerly held the position of Full Professor and Associate Chair at the University of Delaware. Having received both her B.S. and M.S. in Chemical Engineering from Johns Hopkins University, and her PhD in Chemical Engineering from the University of Illinois at Urbana-Champaign, Robinson has earned many honors, including a DuPont Young Professor Award, and a National Science Foundation Presidential Early Career Award for Science and Engineering. She is also a fellow of both the American Institute for Medical and Biological Engineering, and the American Institute of Chemical Engineers.
|Robyn Barfield, PhD||Catalent|
Group Leader, Chemical Biology
No bio available
|Kim De Keersmaecker, PhD||Catholic University Leuven|
Assistant Professor & Head, Lab for Disease Mechanisms in Cancer
Kim De Keersmaecker obtained a PhD in the field of cancer biology at KU Leuven (Belgium) in 2008. From 2008 till 2010, she performed postdoctoral research at Columbia University (New York, USA) with Prof. Adolfo Ferrando, studying the role of transcription factor TLX1 in T-cell leukemia. During a second postdoc at KU Leuven (2010-2013), she undertook exome sequencing in T-cell leukemia patients and discovered somatic mutations in ribosomal proteins in cancer. In 2014, Kim received an ERC starting grant and established an independent research lab at KU Leuven studying the role of somatic ribosome mutations in cancer. The excellence of her research is illustrated by publications in leading journals such as Nature Genetics, Nature Medicine, Nature Communications and Molecular Cell.
|Ken Riker||Celgene Corp|
Director, Product Quality
Over the last 16 years, Ken Riker has led Quality teams to develop and execute filing strategies for three successful global filings for biologics. Most recently he led the effort to evaluate the risk associated with the integrated control strategy for Celgene’s first cell therapy product. He lives in the Seattle area.
|Joel Goldstein, PhD||Celldex Therapeutics Inc|
Senior Director R&D
Joel Goldstein received his PhD in molecular biology from the University of Medicine and Dentistry of New Jersey (UMDNJ) in 1991. He then did his postdoctoral work at Bristol-Myers Squibb (BMS) on antibody fusion proteins prior to joining Medarex in 1994. His role at Medarex was initially to develop bispecific antibodies and fusion proteins, which then evolved into developing antibody production platforms for manufacture. Joel moved back to BMS in 2009 where he continued to lead a team developing manufacturing cell lines for the company’s biologics programs. He then joined Celldex Therapeutics in 2014 to help manage R&D efforts, including establishing antibody engineering and bispecific antibody design strategies for the company’s pipeline.
|Michael Yellin||Celldex Therapeutics Inc|
Vice President Clinical Science
No bio available
Head, Early Discovery
No bio available
|Magdalena Tary-Lehmann, MD, PhD||Cellular Technology Ltd|
Dr. Magdalena Tary-Lehmann is Co-Founding Scientist and CSO for Cellular Technology Limited (CTL). Dr. Tary-Lehmann received her MD and PhD, both from the University of Tübingen, Germany. Her postdoctoral training in Immunology was at the University of California, Los Angeles. She moved thereafter to Case Western Reserve University, where she was awarded tenure and appointed as Associate Professor in the Department of Pathology. As Chief Scientific Officer for CTL she oversees the performance of immunology assays in CTL’s GCP, GLP- and CLIA compliant contract laboratory for various pharmaceutical and biotechnology clients.
Peggy Sotiropoulou joined Celyad in 2017. As Director of the R&D department, she leads a broad-ranging internal research program that aims to develop new strategies in CAR T cell design to target haematological and solid malignancies. Prior to Celyad, Peggy spent 17 years in Academic research in oncology and immunooncology. Before moving to industry, Peggy was associate Professor in the Université Libre de Bruxelles, in Brussels, Belgium, leading research in fundamental oncology and published landmark papers in top tier scientific journals. The aim of Peggy in Celyad is to translate cutting-edge research and innovation into actual treatments for patients.
|Nels Thorsteinson||Chemical Computing Group|
Scientific Services Manager, Biologics
Nels Thorsteinson is a Scientific Services Manager specializing in biologics applications for CCG. He is responsible for providing scientific support, programming custom applications, instructing at workshops, presenting at conferences, and guiding CCG's 3D biologics applications development. Nels majored in biomedical computing and graduated focusing on bioinformatics and computational chemistry.
|M. Eric Kohler, MD, PhD||Children's Hospital Colorado|
Instructor, Blood and Marrow Transplant and Cellular Therapeutics, Center for Cancer and Blood Disorders
No bio available
|Conrad Russell Cruz||Childrens Natl Health System|
Director, Translational Research Labs & Assistant Professor, Center for Emerging Technologies Immune Cell Therapy
Dr. Cruz is an Assistant Professor at Children's National Hospital in Washington DC, with over a decade's experience working on cell-based therapies for cancer and infectious disease. He is currently developing NK cell and T cell-based therapies (both expanded and gene modified) for brain tumors and HIV.
|Timothy Schofield||CMC Sciences, LLC|
Owner and Consultant
Tim Schofield is the Owner & Consultant at CMC Sciences, LLC. Prior to starting his own consulting business Tim worked at: GSK as a Senior Advisor in Global Vaccines Technical R&D, and previously a Director in US Regulatory Affairs; MedImmune as a Senior Fellow in Analytical Biotechnology; Arlenda as US Managing Director and Head of Nonclinical Statistics; and Merck Research Laboratories heading the Nonclinical Statistics department. Tim received a Bachelor of Science degree in Mathematics from Lafayette College, and a Master of Arts degree in Statistics and Operations Research in 1976 from the Wharton School of the University of Pennsylvania. Tim is a member of the USP Statistics Expert Committee and has participated in industry initiatives related to Quality by Design, analytical method development and validation, stability and specifications. He is the Chairman of the IABS Publications Committee and a Guest Researcher at NIST.
|Samuel Sternberg, PhD||Columbia University|
Assistant Professor, Biochemistry & Molecular Biophysics
Samuel Sternberg, PhD, received his B.A. from Columbia University in 2007, graduating summa cum laude, and his Ph.D. in Chemistry from the University of California, Berkeley in 2014. After serving as Group Leader of Technology Development at Caribou Biosciences, Inc., he moved back to Columbia University, where he runs a research laboratory and is an assistant professor in the Department of Biochemistry and Molecular Biophysics. Sam's research focuses on RNA-guided bacterial immune systems (CRISPR-Cas) and on the development of these systems for genome engineering. In addition to publishing his work in leading scientific journals, he recently co-authored a popular science trade book together with Jennifer Doudna, entitled A Crack in Creation, about the discovery, development, and applications of gene-editing technology.
|Christopher Alabi||Cornell University|
Assoc Prof, Chemical & Biomolecular Engineering
Christopher Alabi began his research career as an undergraduate researcher in synthetic organic chemistry under the direction of Dr. David Schuster at NYU. Upon receiving his B.S. in Chemistry from NYU and B.E. in Chemical Engineering from Stevens Institute of Technology, he went on to pursue a graduate degree in Materials Chemistry at California Institute of Technology with Dr. Mark Davis. He then moved to MIT in 2009 and served as NIH Postdoctoral Fellow with Dr. Langer and Anderson. Chris Alabi joined the Cornell faculty in 2013 as an Assistant Professor in the School of Chemical and Biomolecular Engineering. He has won several awards during his short tenure at Cornell including the PhRMA Foundation Research Starter Award, NSF CAREER Award, the 2016 Cornell Engineering Research Excellence Award, the 2017 Tau Beta Pi Professor of the Year Award and the 2018 PMSE Young Investigator Award. In 2019, Chris Alabi was promoted to Associate Professor with Indefinite Tenure. Research in the Alabi lab seeks to understand how the composition and sequence of a macromolecular chain affects its chemical, structural and biological properties with an eye towards engineering sustainable materials and biomolecular therapeutics.
With over 10 years of experience in the membrane proteins field, Dr. Rony Nehmé has a deep and solid understanding of GPCRs biology, pharmacology and structural studies. He was an Investigator Scientist in the lab of Prof. Chris Tate (MRC-LMB in Cambridge) prior to joining Creoptix in 2018 as an Application Scientist. He holds a PhD in molecular biology from the Université de Nice-Sophia Antipolis in France.
|James McNally||CRISPR Therapeutics|
Executive Director & Head, Research & Clinical Assays
Jim McNally is Head of Research, Preclinical and Clinical Assays, CRISPR Therapeutics. He gained extensive experience in immunogenicity strategy, bioanalytical support and scientific oversight of outsourcing of large molecule programs at EMD Serono and at Shire. Previously, he was the lead of the Clinical Assay Development, Validation and Testing bioanalytical group at Pfizer based in Andover, MA. The group was responsible primarily for developing assays to support pharmacokinetic and immunogenicity analysis of the Pfizer large molecule portfolio. Prior to joining Pfizer in 2010, Jim held similar roles in the Clinical Lab Sciences group at Genzyme and Immunobiology group at Repligen. A graduate of the Microbiology and Virology Ph.D. program at LSU Medical Center in 1998, Jim has a special interest in immunomodulation and immunogenicity of biotherapeutics.
|Catherine Owczarek, PhD||CSL Ltd|
Dr Catherine Owczarek is the Director of the Recombinant Protein Expression Group (CSL Limited) located at the Bio21 Institute in Melbourne, Australia. After gaining a PhD at the John Curtin School of Medical Research, Canberra, she completed her post-doctoral studies at the Sir William Dunn School of Pathology in Oxford, the Walter and Eliza Hall Institute in Melbourne and then was a Senior Research Fellow at the Monash Institute of Medical Research in Melbourne. Since joining CSL Limited Catherine has led the CSL Research Group’s efforts in the successful development of programs producing mammalian-derived recombinant proteins using transient expression systems. She is involved in a range of CSL’s early phase drug discovery and development campaigns and has experience in early development clinical development programs of therapeutics for the prevention and/or treatment of human diseases.
|Liming Liu||Curon Biopharmaceuticals Shanghai Co Ltd|
Senior Vice President & Head, Product Development
Dr Liu currently serves as Senior Vice President of Curon Biopharmaceuticals Co. Ltd. He obtained his Ph.D. in immunology at University of Oxford followed by several years’ postdoc work at Harvard University before working in biotech industry in early 2000. Dr Liu has extensive experience in the discovery and development of mAbs and Fc-fusion proteins. He was the head of Immunology group of Syntonix Pharmaceuticals (acquired by Biogen, then Sanofi), working on mAb and Fc-fusion molecule discovery programs. Prior to joining Curon Biopharmaceuticals, He was a Senior Principal Scientist of Merck Research Laboratories for 12 years at the department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism (PPDM), responsible for more than a dozen of Merck Biologics programs including monoclonal antibodies and Fc-fusion proteins from discovery to development and regulatory filings.
|Siew Schleyer||CytomX Therapeutics Inc|
Director, Oncology Research
Siew Schleyer is currently Director of Oncology Research at CytomX Therapeutics. Prior to joining CytomX, she led biotherapeutics research programs in Oncology at Novartis, where she oversaw large molecule programs from early stage research through entry into the clinic. In addition, she worked at Chiron, identifying and validating novel oncology targets, and has authored publications and patents in the field of oncology. Siew obtained her Ph.D. in Immunology at Harvard.
|Jiwon John Lee||Dartmouth College|
Assistant Professor, Engineering
Jiwon Lee is Ralph and Marjorie Crump Assistant Professor in Thayer School of Engineering at Dartmouth College. He received his BA in Molecular and Cell Biology from the University of California, Berkeley, and his PhD degree in Chemical Engineering at the University of Texas at Austin. His research group is interested in developing cutting-edge technologies for immune profiling to understand how antibody repertoires impact health and disease in the context of infectious disease, autoimmunity, and cancer, then applying this knowledge as a guide for engineering next-generation prophylactics and therapeutics.
|Jacob Glanville||Distributed Bio|
Founding Partner & CEO
Jake Glanville is an entrepreneur and computational immuno-engineer. He has developed multiple seminal methods in the fields of high-throughput antibody repertoire sequencing, repertoire decoding algorithms, single-cell TCR receptor & phenotype sequencing, and computationally guided antibody library engineering.
|Priya Kishnani||Duke University|
Professor, Pediatric Medical Genetics
Dr. Priya Kishnani is Chief, in the division of Medical Genetics at Duke University Medical Center as well as Director of the YT and Alice Chen Pediatrics Genetics and Genomics Center. Dr. Kishnani moved to the United States in 1991, after completing a residency in Pediatrics in Mumbai, India. She went on to do a second residency in Pediatrics as well as a Fellowship in Genetics and Metabolism at Duke University Medical Center. Shortly after, she joined the faculty at Duke University and has worked as a Professor of Pediatrics in the Pediatrics and Medical Genetics departments. Dr. Kishnani is certified by the American Board of Medical Genetics and the American Board of Biochemical Genetics. She also serves as the Director of the Lysosomal Storage Disease Program, Biochemical Genetics Training Program, and Metabolic Clinic at DUMC.
|Nicoletta Bivi||Eli Lilly & Co|
Director, Experimental Medicine La
Nicoletta Bivi received her Master’s degree in Biotechnology from the University of Trieste in 2003 and subsequently completed a PhD in Molecular Biology from the University of Udine in 2008. Dr. Bivi joined Eli Lilly and Company in 2012 from Indiana University School of Medicine, where she was an Assistant Professor.
In her current role as the Director of Assay Development, Dr Bivi leads a team of scientists who develop novel biomarker, target engagement, and immunogenicity assays to support all therapeutic areas and phases of Eli Lilly and Company’s portfolio. In addition, Dr Bivi’s laboratory contributes to the assessment of pre-clinical immunogenicity risk.
Dr. Bivi’s interests include immunoassays and mechanisms of immunogenicity. Recently, her laboratory was the first to demonstrate that pre-existing reactivity assessment of biotherapeutics can predict clinical immunogenicity and the epitope(s) targeted by the anti-drug antibodies.
Dr. Bivi is the author or co-author of more than 20 peer-reviewed scientific papers.
|Kristin Hollister||Eli Lilly & Co|
Research Scientist, Experimental Medicine Lab
Kristin Hollister, Ph.D., is a Senior Research Scientist in the Laboratory for Experimental Medicine (LEM) at Eli Lilly and Company, where she functions as an immunogenicity Clinical Advisor. She has worked on numerous clinical development teams from pre-Phase 1 through marketing approval and post-launch activities. She additionally acts as the Communications Leader for LEM and their assay development and validation work. Prior to joining Lilly, Kristin earned her Ph.D. in Microbiology and Immunology, with a focus in follicular helper T cells, from the Indiana University School of Medicine in 2014. Her pervious roles in the company include work in Clinical Pharmacology, Global Patient Health Outcomes, and submission and launch support in the Biomedicines business unit.
|Helen Kotanides||Eli Lilly & Co|
Senior Research Advisor
No bio available
|John Rhoden||Eli Lilly & Co|
Senior Research Scientist
John Rhoden, Ph.D. is a Principal Research Scientist in the Department of Drug Disposition at Eli Lilly and Company. He received his B.S. in Chemical Engineering from N.C. State University and a Ph.D. in Chemical Engineering from M.I.T. under the guidance of Prof. K. Dane Wittrup, after which he joined Eli Lilly and Company in 2012. At Lilly, Dr. Rhoden serves as a large molecule ADME project leader on discovery and early development project teams in a variety of therapeutic areas including oncology, immunooncology, autoimmunity, and kidney disease. Dr. Rhoden’s professional interests lie in using simple mathematical models to understand complex systems, interrogate hypotheses, and guide experiment design and interpretation.
|Gregory Adams, PhD||Elucida Oncology Inc|
Dr. Adams is Chief Scientific Officer of Elucida Oncology, a clinical stage company developing antibody-toxin fusion proteins for the treatment of cancer. In this role he is responsible for guiding the development of the company’s pipeline assets. Before moving to biotech, Dr. Adams was the Director of Biological Research and Therapeutics and previously co-led the Developmental Therapeutics Program at the Fox Chase Cancer Center, an NCI designated comprehensive cancer center in Philadelphia. Dr. Adams is an immunologist with over 30 years of experience in developing antibody-based agents for the treatment and detection of cancer. He received a Ph.D. in Immunology from the University of California at Davis in 1991. He joined Fox Chase Cancer Center in Philadelphia where he led a laboratory focused on developing antibodies and antibody-drug conjugates for the treatment of breast, ovarian and renal cancer. Dr. Adams serves on the Editorial Boards of Cancer Immunology Research, MAbs and Cancer Biotherapy & Radiopharmaceuticals. He has served on the Scientific Advisory Boards of a number of biotechnology companies including Endo Pharmaceuticals, Symphogen, Avipep, Viventia Bio, AvidBiologics, Xerion, Fabrus, Integral Molecular and YM Biosciences.
|Seema Kumar, PhD||EMD Serono R&D|
Associate Director Drug Metabolism & Pharmacokinetics
Seema Kumar is currently an Associate Director and a DMPK senior project representative at EMD Serono Inc. (a business of Merck KGaA, Germany). In her role, Dr. Kumar is responsible for overall NBE drug disposition support including DMPK/ADME, Bioanalysis (BA) and Immunogenicity strategy for biotherapeutics from the concept generation through discovery and development stages. Previously, Dr. Kumar led regulated Bioanalytical group in BioMedicine Design (formerly PDM-NBE) department at Pfizer. The group provided regulated (GLP/GCP) BA support including assay development, validation and sample analysis for PK, ADA and Nab assessments for pre-clinical and clinical development of Pfizer’s large molecule portfolio. Dr. Kumar also managed Core Automation Team (CAT) engaged in automated large-molecule bioanalysis using Hamilton robotic liquid handlers. Prior to joining Pfizer, Dr. Kumar had served at roles of increasing responsibility as Director of Quality Control and Director of CLIA certified Clinical Bioanalytical Lab at XBiotech USA Inc. Dr. Kumar holds a PhD in Biophysical Chemistry from Johns Hopkins University and has published several publications in peer-reviewed journals and contributed to several book chapters. Dr. Kumar has also given numerous talks in various national and international scientific conferences and meetings. Dr. Kumar has a special interest in Pharmacokinetics and Drug Disposition of multidomain biotherapeutics.
|Simon Friedensohn||ETH Zurich|
Graduate Student, Biosystems Science & Engineering
Simon Friedensohn is a PhD candidate in Sai Reddy’s Laboratory of Systems and Synthetic Immunology at ETH Zurich. His research work focuses on developing both experimental as well as computational methods for high-throughput immune repertoire sequencing. He holds a BSc and MSc in Biotechnology from ETH Zurich. Previous to joining the Reddy lab, he completed a scientific internship at Roche where he worked on high-throughput (mi)RNA profiling for comparative genomics.
|Rodrigo Vazquez-Lombardi||ETH Zurich|
PostDoc Lab for Systems & Synthetic Immunology, Biosystems Science & Engineering
Dr. Rodrigo Vazquez-Lombardi is a research scientist specializing in therapeutic protein engineering and immunology. As part of his PHRT Postdoctoral Fellowship at ETH Zurich (D-BSSE, Basel), he is currently developing novel tools for use in T cell immunotherapy applications.
|Kurt Wüthrich, PhD||ETH Zurich|
Kurt Wüthrich is the Cecil H. and Ida M. Green Professor of Structural Biology at Scripps Research, La Jolla, CA, USA, Professor of Biophysics at the ETH Zürich, Zürich, Switzerland, and Distinguished Senior Professor at the iHuman Institute, ShanghaiTech University, Shanghai, China. For 50 years, Wüthrich groups at the ETH Zürich, at Scripps Research and at the iHuman Institute have used nuclear magnetic resonance spectroscopy (NMR) for research in structural biology. Contributions include the method of protein structure determination with NMR in solution, and the use of the principles of transverse relaxation-optimized spectroscopy (TROSY) for NMR experiments with large supramolecular assemblies. Applications over the years were focused on differentiation in higher organisms, immune suppression and neuropathology. As of April 2019, research using NMR techniques is continued at ShanghaiTech University, with a focus on transmembrane signal transfer by G protein-coupled receptors (GPCRs). At Scripps Research and the ETH Zürich, projects on the general theme “healthcare in the ageing human societies of the 21st century” are pursued, mainly considering the impact of sarcopenia on the human healthspan. Kurt Wüthrich’s achievements have been recognized by the Prix Louis Jeantet de Médecine, the Kyoto Prize in Advanced Technology, the Nobel Prize in Chemistry, and by a number of other awards and honorary degrees.
|Dario Neri||ETH Zurich (Swiss Federal Institute of Technology)|
Prof, Chemistry and Applied Biosciences
Dario Neri was born in Rome on 1 May 1963, but grew up in Siena (Italy). He studied Chemistry at the Scuola Normale Superiore of Pisa and earned a PhD in Chemistry at the Swiss Federal Institute of Technology (ETH Zürich), under the supervision of Professor Kurt Wüthrich (Nobel Prize Chemistry 2002). After a post-doctoral research internship (1992-1996) at the Medical Research Council Centre in Cambridge (UK), under the supervision of Sir Gregory Winter (Nobel Prize Chemistry 2018), he became professor at ETH Zürich in 1996. Dario Neri is currently Full Professor of Biomacromolecules at the Department of Chemistry and Applied Biosciences, ETH Zürich. The research of the Neri group focuses on the engineering of therapeutic antibodies for the therapy of cancer and other angiogenesis-related disorders and on the development of DNA-encoded chemical libraries. Dario Neri is a co-founder of Philogen (www.philogen.com), a Swiss-Italian biotech company which has brought various antibody products into multicenter clinical trials for the treatment of cancer and of chronic inflammatory conditions. Dario Neri has published more than 400 articles in peer-reviewed scientific journals. He is the recipient of the ISOBM Abbott Prize 2000, of the Amgen-Dompe’ Biotec Award 2000, of the Mangia d’Oro 2001, of the Prous Award 2006 of the European Federation of Medicinal Chemistry, of the Robert-Wenner-Prize 2007 of the Swiss Cancer League, of the SWISS BRIDGE Award 2008, of the Prix Mentzer of the French Medicinal Chemistry Society in 2011, of the Phoenix Prize 2014 and of an ERC Advanced Grant in 2015.
|Jennifer Lin-Jones||Eurofins DiscoverX|
Senior Group Leader, Assay Development, Research & Development
Cell biologist at Eurofins DiscoverX overseeing development of cell-based assays for drug discovery and pharmacology, across multiple therapeutic areas and target classes.
|John LaCava, PhD||European Research Institute for the Biology of Ageing|
Group Leader, Lab of Macromolecules & Interactomes
Dr. John LaCava is an NIH-funded investigator, Research Faculty member at The Rockefeller University, and a Group Leader at the European Research Institute for the Biology of Ageing. He focusses on the development of affinity proteomic methods to capture and characterize endogenous macromolecules – lately pursuing molecular pathophysiology and associated perturbations in protein interaction networks.
|Markus Hildinger, PhD||evitria AG|
Dr. Markus Hildinger (CEO, evitria AG) has over 25 years of experience in engineering and production of antibody-based therapeutics. Recognizing the need for fast and cost-effective generation of antibodies, he founded evitria AG in 2010. Today, his company reaches customers around the globe, serving a broad range of clients from academia to global biopharmaceutical companies. Dr. Hildinger has published more than 30 peer-reviewed scientific articles and is co-inventor on numerous patents and patent applications.
|Maria Gonzalez-Pajuelo, PhD||Fairjourney Biologics SA|
Since 2012 Maria Gonzalez-Pajuelo is co-founder and Chief Scientific Officer at FairJourney Biologics, a company that provides fast and high quality solutions for monoclonal antibodies needs. Maria initiated her career in the antibody field in 2006 at Ablynx, where she worked on the identification of Nanobodies® as Scientist-Team leader until 2012. Maria is co-inventor in 13 patent applications on antibodies and on antibodies technologies and co-author on 13 Peer Reviewed Publications.
|Bob Bahram Valamehr||Fate Therapeutics Inc|
Chief Developmentelopment Officer
Bob Valamehr is the Chief Development Officer at Fate Therapeutics, overseeing the company’s early development activities including “off-the-shelf” cell therapy products derived from the company’s induced pluripotent stem cell platform. Previously, Dr. Valamehr was the Vice President of Cancer Immunotherapy at Fate and prior to that played key scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center) and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer. He has co-authored numerous studies and patents related to stem cell biology, oncology and materials science. Dr. Valamehr received his Ph.D. from the Department of Molecular and Medical Pharmacology at UCLA, his M.B.A. from Pepperdine University and his B.S. from the Department of Chemistry and Biochemistry at UCLA.
No bio available
|Wojciech Jankowski||FDA CBER|
Commissioners Fellow & Biologist, Center for Biologics Evaluation & Research
Dr. Jankowski is a research reviewer with the US Food and Drug Administration in the Office of Tissues and Advanced Therapies. He is part of an active research laboratory and his research interests lie in the regulatory-science associated with the licensure of the next generation of therapeutic proteins. A key focus of his research activities has been to understand the immune response to protein therapeutics, which can significantly affect the efficacy and safety of these drugs. He uses a combination of computational, in vitro and ex vivo approaches in his work. Dr. Jankowski received his Ph.D. from Rutgers University, NJ and was subsequently selected for the highly competitive Commissioner’s Fellowship program at the FDA. His research has been published in high impact journals such as Nature and Nature Chemical Biology.
|Chava Kimchi-Sarfaty, PhD||FDA CBER|
Acting Deputy Associate Director Research, Plasma Protein Therapeutics
Chava Kimchi-Sarfaty currently leads a group at the FDA within the Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies (OTAT) that investigates various blood coagulation factors with a specific focus on the genetic determinants of coagulation factor biosynthesis and structure. She is also the Acting Deputy Associate Director for Research of the Office. She reviews and chairs pre-INDs, INDs and BLAs for recombinant proteins and plasma derivatives products such as von Willebrand factor, ADAMTS13, factor VIII, FIX, thrombin and fibrinogen.
|Mike Singer||FDA CBER|
Medical Officer, Clinical Evaluation & Pharmacology, Center for Biologics Evaluation & Research
No bio available
|Leopold Kong||FDA CDER|
Dr. Kong has been a biologics quality and immunogenicity reviewer with the Office of Biotechnology Products, Center for Drugs- FDA since 2017. He received his PhD on Structure-Based Vaccinology in 2010 from the University of Oxford, Oxford, England, UK. Since joining the FDA, Dr. Kong has accrued regulatory experience in reviewing innovator biologics and serves as an active member of the Immunogenicity Working Group in the Office of Biotechnology Products.
|Perry Wang, PhD||FDA CFSAN|
Dr. Perry G. Wang worked in the pharmaceutical and medical-device industry from 2000 to 2008. He received his Ph.D. degree at Oregon State University. Dr. Wang currently works at FDA as a chemist. In addition to over twenty peer-reviewed publications, he has edited and co-edited five books: "High-Throughput Analysis in the Pharmaceutical Industry", "Monolithic Chromatography and Its Modern Applications", "Hydrophilic Interaction Liquid Chromatography (HILIC) and Advanced Applications", "Counterfeit Medicines", and "High-Throughput Analysis for Food Safety". His expertise focuses on high throughput analysis and validation by LC-MS. He prepares and teaches this course in his own capacity but not as an employee of the FDA. He has been invited to teach this course at ASMS since 2015.
|Francois-Thomas Michaud||Feldan Therapeutics|
Dr. François-Thomas Michaud co-founded and became CEO of Feldan in 2007 while completing his PhD degree in chemical engineering at Laval University. Through the years, Dr. Michaud and his team worked on a research project that led to the inception of a cell-penetrating proprietary technology, the Feldan Shuttle. This technology, which gives access to a wide range of intracellular therapeutic targets, has the potential to bring a whole new class of therapies to the clinic. Over the years, Dr. Michaud’s value-creating vision shaped the business model of the company, at the center of which resides the Feldan Shuttle.
Through his leadership, exceptional human qualities and determination, Dr. Michaud has successfully built in Québec City a sustainable organization that today stands alongside biopharmaceutical global leaders. In addition to position itself as one of the top Canadian SMI-biotech leaders, Dr. Michaud is actively engaged in the business, academic and entrepreneurial communities of the Province of Québec as an administrator, speaker and mentor.
Dr. Maureen O’Connor-McCourt brings her TGF-beta expertise, which began in her post-doctoral training in the laboratory of Drs. Michael Sporn and Anita Roberts, to Forbius as Chief Scientific Officer. She has published over 100 peer-reviewed manuscripts, including over 50 publications in the TGF-β field. Maureen is an expert in the discovery and development of targeted biological therapies. Prior to joining Forbius, Maureen was Principal Research Officer and Section Leader at the Canadian National Research Council (NRC). While at NRC, Maureen served as a Scientific Leader of NRC's Biologics Program, a pan-Canadian network of over 10 research teams. Under her leadership, this program established a successful track record in developing innovative protein therapeutics.
|Colin Correnti, PhD||Fred Hutchinson Cancer Research Center|
Senior Research Scientist, Clinical Research
My research has always been at the interface of biophysics and immunology and has focused on developing new platform technologies that empower both basic scientists and clinicians to bring new biologics into the clinic. Supporting this I co-developed a robust lentiviral-based protein expression platform called Daedalus, which has completely revolutionized the speed at which we can bring new protein-based biologics into and through preclinical studies. Using this platform, I founded the Molecular Design and Therapeutics Core, which brings these technologies to every investigator at the Fred Hutchinson Cancer Research Center. I now support over a dozen preclinical pipelines with novel, custom-engineered proteins ranging from novel antibody therapeutics to knottin-based peptide-drug conjugates. I now have over 12 years of experience in protein engineering and biophysics, and 5 years of experience managing a highly productive, mammalian protein expression core, which provides not only next generation proteins to investigators but also a rich training environment for research technicians, graduate students and post-doctoral fellows. Currently I lead multiple immunotherapy drug discovery efforts that involve antibody discovery and engineering for CAR- T cell and bispecific therapies.
|Serguei Kozlov, PhD||Frederick National Laboratory for Cancer Research (NCI)|
Principal Scientist/PM, Team Leader Preclinical Technology and Optimization Team, Center for Advanced Preclinical Research
Internationally recognized expert in advanced methodologies for developing genetically and biologically engineered preclinical murine disease models for studies of the molecular mechanisms of carcinogenesis, tumor immune response, immune surveillance, and inflammation, mechanisms of drug resistance, implication of cancer stem cells, etc.; and to explore such models for preclinical drug development, disease systems analyses and biomarker discovery. Initiated, supervised, and successfully conducted multiple research projects and independent large-scale research and development programs aimed at investigation of molecular mechanisms governing carcinogenesis, biomarker discovery and preclinical drug evaluation in various mouse models. Oversees the preclinical technology development operations at the Frederick National Laboratory Center for Advanced Preclinical Research – an innovative preclinical cancer modeling and drug development initiative based on genetically engineered murine models – with senior management responsibilities. Co-authored over 70 scientific papers, book chapters and original works in peer-reviewed journals.
|Richard Buick, PhD||Fusion Antibodies plc|
Richard Buick has more than 20 years’ experience in the biopharmaceutical industry and has a PhD in Immunology from Queen’s University Belfast. He joined Fusion Antibodies as a Director and was appointed CTO in 2011, managing all scientific projects and patent portfolios. Fusion Antibodies was admitted to the London Stock Exchange in 2017 and Richard has been expanding the company’s service areas including affinity maturation by in silico design and antibody discovery by B-cell cloning.
|Arnd Bradenburg, PhD||Genedata|
Head, Professional Services, Genedata Expressionist
Arnd Brandenburg joined Genedata in 2005 and is heading the Professional Services team of the Expressionist business unit. Before joining Genedata, Arnd worked as a theoretical physicist at DESY, Hamburg, doing research in particle physics and cosmology. He did his PhD in physics at the university of Heidelberg and is a lecturer for bioinformatics and systems biology at the university of Freiburg.
|Amanda Fitzgerald, PhD||Genedata Inc|
Senior Scientific Consultant, Biologics
Amanda Fitzgerald leads a team of scientific consultants at Genedata, who provide solutions for organizations with large molecule and data management needs. She received her doctorate in Biochemistry and Molecular Pharmacology from the University of Massachusetts Medical School and has pharmaceutical industry experience in biotherapeutic discovery and production groups, including scientific support for strategic alliances and development of a high-throughput protein production platform at Pfizer.
|Takashi Ebihara, PhD||GeneFrontier Corp|
Takashi is COO of GeneFrontier Corporation (GFC) since 2010. Takashi got his PhD for the research of cell-free protein expression system at Tokyo Institute of Technology in 2000 and joined in VC in life science industry. At 2003, Takashi was involved in establishment of GFC and fully committed to business development of GFC from the beginning.
|Paul Carter, PhD||Genentech Inc|
Senior Staff Scientist & Senior Director Antibody Engineering
Paul Carter is a Senior Director and Staff Scientist in the Antibody Engineering Department at Genentech, Inc. His research interests focus on creating new antibody technologies and applying them to develop future generations of antibody therapeutics. His accomplishments in drug development include initiating the antibody humanization program at Genentech. He is a co-inventor of 5 antibodies that have entered clinical development including one that later became a commercial product (Herceptin). He is a co-inventor of “knobs-into-holes” technology used to create a one-armed antibody and at least 4 bispecific antibodies that have entered clinical development. He also invented technology for high-level antibody fragment expression in E. coli including a Fab fragment that subsequently became a commercial product (Lucentis). He is an inventor or co-inventor on at least 43 issued US patents. He has published more than 100 scientific publications that together have been cited >15,500 times. He received a BA in Natural Sciences from Cambridge University and his Ph. under Sir Gregory Winter, PhD and FRS at the MRC Laboratory of Molecular Biology in Cambridge. He was a Postdoctoral Fellow with Dr. James A. Wells at Genentech. He has over 30 years of experience in biotechnology including Genentech (1986-2000 and 2010-present), Immunex/Amgen (2000-2003), Seattle Genetics (2003-2008) and VLST (2008-2009). His professional experience also includes heading the postdoctoral programs at Genentech, Immunex and Amgen.
|Sivan Cohen||Genentech Inc|
Scientist, Cell Biology
No bio available
|Avinash Gill||Genentech Inc|
Senior Scientific Manager, Antibody Engineering
Avinash Gill received his Ph.D. in Biochemistry and Structural Biology from Dartmouth College and completed his post-doctoral research at the Thayer School of Engineering at Dartmouth. In his previous roles, he has worked at ImmunoGen, Bio-Architecture Lab and Sutro Biopharma. His research interests include protein purification, biochemical assay development, protein engineering, affinity analysis, automated process development and bioinformatics. Currently he is Sr. Scientific Manager in the Antibody Engineering department at Genentech where he oversees efforts in automated high-throughput protein production, design, implementation and maintainence of automated workflows for antibody discovery and engineering, as well as software development for efficient process management. His research group focuses on developing and implementing automated high-throughput technologies for production and characterization of naturally derived and engineered antibodies, antibody fragments as well as other novel therapeutic formats.
|Teemu Junttila, PhD||Genentech Inc|
Dr. Junttila joined Genentech in 2006. Currently his research is focused in developing Genentech’s T cell dependent bispecific (TDB) antibodies and he is responsible of multiple CD3-bispecific molecules in various stages, ranging from early stage research to clinical development.
|James Koerber, PhD||Genentech Inc|
Scientist, Antibody Engineering
JT received his PhD in Chemical Engineering from the University of California Berkeley where he developed novel protein engineering strategies for viral gene therapy. He then completed a post-doc with Jim Wells at the University of California San Francisco where he developed a novel structure-based design platform to generate phospho-specific antibodies. At Genentech, he works in the collaborative environment to discover novel biology and transformative drugs. Our goal is to advance new therapies to patients by tackling challenging targets and engineering around drug delivery barriers.
|Greg Lazar||Genentech Inc|
Director & Senior Scientist, Antibody Engineering
Greg Lazar received his BS in Molecular & Cell Biology and Chemistry from Penn State, his PhD in Molecular & Cell Biology from the University of California at Berkeley, and did postdoctoral research at the University of Cambridge, UK. Previously he led research groups at Eli Lilly and Xencor. Currently he is Director and Senior Scientist in Antibody Engineering at Genentech where he oversees antibody technology platforms, high-throughput protein production, and infrastructure for automation, software, and informatics. His research group is focused on the development of novel antibody technologies to enable next generation therapeutics to treat unmet medical needs in oncology and neuroscience.
|Shahram Misaghi, PhD||Genentech Inc|
Senior Scientist, Early Stage Cell Culture
I am a senior scientist at the Cell Culture department in Genentech. I have been in this role since 2010. My research involves improving/innovating processes that result in generation of cell lines expressing bio-therapeutics (proteins and antibodies used as drugs) that grow better and yield higher titers with better product quality attributes. Bachelor: University of California Berkeley, Molecular and Cell Biology. PhD: Harvard University, in Biological and Biomedical Sciences. Post-doctoral fellow at Massachusetts Institute of Technology (MIT). Post-doctoral fellow at Genentech.
|Idris Mustafa, MS||Genentech Inc|
Lead Automation Scientist, BioMolecular Resources
Idris Mustafa is a Lead Automation Scientist and Software Architect, currently residing in the San Francisco Bay Area, leading departmental automation efforts within the Biomolecular Resources Organization at Genentech, a member of the Roche Group. Idris has spent the last 10 years bridging the gap between drug discovery and technology using advanced control machines, building custom algorithms, and expanding his breadth of knowledge. He has also dedicated much of his career to creating software products that increase efficiency in the lab and change the face of the way robots, databases and people interact. Idris' research is at the cutting edge of liquid-handling robotics innovation; leveraging 3D-printing technologies and machine learning concepts to drive productivity. Idris believes his "Faith in God and passion to optimize the human condition", will inevitably lead to future breakthroughs in the world of science and technology.
|Kate Peng||Genentech Inc|
Senior Scientist, Assay Developmentelopment & Technology
Dr. Kate Peng received her Ph.D. in metabolic biology from the University of California Berkeley. Following her post-doctoral training at Berkeley, Dr. Peng worked at biotechnology industry with a focus on developing cell-based methods for high-throughput screening of drug candidates targeting GPCRs. Dr. Peng joined Genentech in 2007 and is currently a Group Leader/Senior Scientist in the Department of BioAnalytical Sciences. Her focus is on development of bioanalytical strategies and methods to enable assessment of the pharmacokinetics, pharmacodynamics, immunogenicity of protein therapeutics from early development to clinical as well as post-marketing stages. Dr. Peng has led bioanalytical effort for supporting the development of protein therapeutics that target cancer immunotherapy, immunology, neurology and cardiovascular disease areas.
|Wendy Sandoval||Genentech Inc|
Senior Scientific Researcher
Wendy is a principal scientist at Genentech. She leads the Translational Mass Spectrometry group within the research organization. Her group focuses on mass spectrometry-based strategies to help elucidate protein structure and function. She has a particular interest in native mass spectrometry and it's evolving role in the biopharmaceutical industry. During her more than twenty years at Genentech Wendy has co-authored 70 papers and edited two books, and is happy that she continue to learn new things every day.
|Benjamin Walters||Genentech Inc|
I am generally interested in how protein structural dynamics drives biological activity and using this information to make better drugs and more stable formulations. Mass spectrometry has proven to be a terrific tool for many questions related to these aims. Currently, my group focuses on applications MS to enable covalent drug discovery and as projects progress in the research portfolio, we use hydrogen exchange measurements in a variety of ways to enhance structure-based drug design and SAR efforts.
I graduated from North Carolina State University with a B.S. in Biochemistry in 2006 and obtained my Ph.D. in Biochemistry and Molecular Biophysics in 2013 from the University of Pennsylvania. I completed an industrial post-doc at Genentech in 2016 and liked it so much I decided to stay.
|Tina Kang||GenScript ProBio|
Senior Scientist, Discovery
Dr. Manzhu Kang received her Ph. D. from the University of California Los Angeles, with a dissertation focusing on the impact of combinatorial therapy on the evolution of drug resistance. Dr. Kang is a senior scientist of antibody research group at GenScript ProBio. She is in charge of the single B cell screening platform for antibody drug discovery.
|Sean Taylor||GenScript USA Inc.|
Field Application Scientist Manager, CPBU
Sean is currently working at GenScript USA Inc as Manager of Field Application Scientist. He has over sixteen years of research, scientific writing and collaborative experience with the life scientists, and over eleven years of experience in education in the life science community in the best practices for experimental design and data analysis in common research techniques and lab equipment. Sean holds a Ph.D degree and a Masters of Business Administration degree from McGill University, Montreal, PQ.
|Claire Davies||Genzyme Corp A Sanofi Co|
After obtaining her PhD from the University of London in 2001, Claire Davies performed her postdoctoral work at the William Harvey Research Institute (WHRI) at Bart’s and The London, Queen Mary's School of Medicine and Dentistry and Joslin Diabetes Center, Harvard Medical School, Boston. Over the last 16 years, Dr Davies has led analytical and CMC teams in product development and analytical method development and validation. Currently, Dr Davies leads Bioanalytics, a group responsible for developing methods and strategies to support process development, product characterization and release and stability testing for therapeutic proteins and gene therapy products in preclinical and clinical development.
|Louis Weiner||Georgetown University|
Professor & Director, Oncology, Lombardi Comprehensive Cancer Cneter
Dr. Louis Weiner is director of Georgetown Lombardi Comprehensive Cancer Center, one of 49 National Cancer Institute (NCI)-designated comprehensive cancer centers in the United States. He holds the Francis L. and Charlotte G. Gragnani Chair and is professor of oncology and chair of the Department of Oncology at Georgetown University Medical Center. He also serves as the Director of the MedStar Georgetown Cancer Institute, a cancer service line serving patients in the Washington DC and Baltimore metropolitan areas. He is responsible for the operation and development of the cancer center, including its research, clinical, and educational missions. The clinical mission includes leading the MedStar-Georgetown Cancer Network in the metropolitan Washington area. Weiner is known for his laboratory and clinical research focusing on new therapeutic approaches that mobilize the patient’s immune system to fight cancer using monoclonal antibodies and other modalities of therapy. His current research focuses on identifying and therapeutically exploiting mechanisms employed by malignant cells to combat immune destruction. Prior to joining Georgetown Lombardi as director in 2008, Weiner served as chairman of the medical oncology department and vice president for translational research at Fox Chase Cancer Center in Philadelphia, PA, and also served as professor in the department of medicine at Temple University School of Medicine. He is an active member of the American Society of Clinical Oncology and the American Association for Cancer Research (AACR), and founded the AACR Cancer Immunology Working Group. He has served as chair of the NCI Board of Scientific Counselors for Clinical Sciences and Epidemiology and as a member of the NCI Clinical Trials Advisory Committee (CTAC). He also served on the NCI’s blue ribbon panel working group on immunotherapy for the National Cancer Moonshot Initiative and the Advisory Panel of the National Institutes of Health (NIH) Center for Scientific Research (CSR), which administers NIH research grants. He is recipient of the 2019 AACR Distinguished Public Service Award. Weiner earned his bachelor degree in biology with honors from the University of Pennsylvania and his M.D. from Mount Sinai School of Medicine. After completing his internship, residency, and service as chief medical resident at the University of Vermont’s Medical Center Hospital, he held clinical and research fellowships in hematology and oncology at Tufts University School of Medicine in Boston.
Investigator, BPRD CI
No bio available
Team Leader, Molecular Design & Engineering
Carlos R. Reis has been working in the Protein Engineering field for over 15 years. During this time, he has worked with several small and large biotech companies at different stages of product development, from discovery to manufacturing. His primary focus has been on protein therapeutics, antibody structure-function relationships, protein and antibody design and developability assessment of biologics during early discovery. He is currently a group leader in Antibody Engineering at GSK located in Stevenage, UK, working at the interface between discovery and development on new protein engineering strategies and technologies to optimize the developability profile of candidate molecules and accelerate their development. Carlos R. Reis received his PhD in Mathematics and Natural Sciences from the University of Groningen, NL, and completed his postdoctoral training in computational biology and cell engineering at UT Southwestern Medical Center in Dallas, USA. His main contributions include the development of novel computational protein design methods to generate potent and selective anti-cancer therapeutics targeting TNFR members, the discovery of new regulatory links between therapeutics and endocytic trafficking and the design of novel effector-based protein engineering strategies to restore self-tolerance in autoimmunity. He is passionate about science, mentorship and applying innovative protein design principles to engineer effective therapies that can potentially save lives.
|Axel Hoos||GlaxoSmithKline Pharmaceuticals|
SVP R&D Goverance Chair, and Therapeutic Area Head for Oncology
Dr. Axel Hoos is Senior Vice President, R&D Governance Chair, and Therapeutic Area (TA) Head for Oncology at GlaxoSmithKline Pharmaceuticals (GSK). He is responsible for discovery and development in Oncology with focus on immuno-oncology, epigenetics, cell therapies and genetic medicine. As R&D governance chair he oversees technical and funding review committees. He returned GSK to Oncology after the divestment of its marketed medicines to Novartis in 2015 and is responsible for GSK's Oncology portfolio focusing on innovative medicines to deliver transformational benefit to patients. Recent portfolio expansion included the acquisition of Tesaro, a co-development partnership with Merck-Serono, and the in-licensing of the first cell therapy active in solid tumors from Adaptimmune. Dr. Hoos also serves as Chairman of the Board of Trustees of the Sabin Vaccine Institute (SVI), a Global Health organization, Director on the Board of Imugene, a biotech company, Co-Director of the Cancer Immunotherapy Consortium (CIC) and Scientific Advisory Board Member of the Cancer Research Institute (CRI). His efforts focus on novel therapies for life-threatening diseases, scientific and technical innovation, and business and scientific collaboration. Through his leadership a paradigm for the development of cancer immunotherapies has been defined, which helped launch the field of Immuno-Oncology (Nat. Rev. Drug Discovery 2016, 15(4):, 235-47). Previously, Dr. Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS) where he developed Yervoy (Ipilimumab), the first life-extending therapy and the first checkpoint inhibitor drug in Immuno-Oncology. The discovery of ipilimumab’s scientific mechanism was honored with the Nobel prize for Physiology or Medicine to Dr. James Allison in 2018. Before BMS, Dr. Hoos was Senior Director of Clinical Development at Agenus Bio (previously Antigenics), a biotech company. Dr. Hoos holds an MD from Ruprecht-Karls-University and a PhD in molecular oncology from the German Cancer Research Center (DKFZ) both in Heidelberg, Germany. He trained in surgery at the Technical University in Munich and further in surgery, molecular pathology and tumor immunology at Memorial Sloan-Kettering Cancer Center in New York City. He is an alumnus of the Program for Leadership Development at Harvard Business School.
|Juan Almagro||GlobalBio Inc|
Founder & Director
Dr. Juan C. Almagro is an internationally recognized expert in engineering and development of antibody-based therapeutics. In part with support from the National Science Foundation, he founded GlobalBio to provide collaborative services in the areas of discovery, optimization and development of biotherapeutics. Prior to founding GlobalBio, he was a Senior Director at Pfizer and Research Fellow and Head of Antibody Design at Johnson and Johnson. Before joining the Pharma/Biotech industry, Dr. Almagro was Visiting Scientist at Florida International University, Affiliated Visiting Scientist at Fred Hutchinson Cancer Research Center, Visiting Professor at Simon Fraser University and Associate Professor and Group Leader at The National University of Mexico. He has authored over 70 publications, encompassing more than 50 peer-reviewed scientific articles, 6 book chapters, and 20 international patents. Dr. Almagro serves as reviewer in Immunology and Protein Engineering journals, as well as for grant agencies in several countries. He has participated in the Scientific Advisory Boards of several Biotech companies, has chaired and given talks and lectures at major domestic and international scientific meetings, and has been expert witness in several Intellectual Property litigations between large biopharma organizations.
|Lars Stöckl, PhD||Glycotope GmbH|
Glycotope Service Division
Lars Stöckl joined Glycotope in 2005 and besides other tasks was responsible for the establishment of the GlycoExpress plattform and for setting up the glyco-analytical lab. Since January 2020 he heads the service department of Glycotope.
Before the appointment at Glycotope he gained experience in cell line engineering and protein chemistry during his PhD and Postdoc at the Robert Koch-Institute /Berlin, the Charite / Berlin and the Breakthrough Breast Cancer Research / London.
|Karin Jooss||Gritstone Oncology Inc|
Karin Jooss, Ph.D. has served as our Executive Vice President of Research and Chief Scientific Officer since April 2016. Prior to Gritstone, from May 2009 to April 2016, Dr. Jooss served as head of cancer immuno-therapeutics in the vaccine immuno-therapeutics department at Pfizer, Inc., or Pfizer, a public pharmaceutical company, where she was also a member of the vaccine immuno-therapeutics leadership team and served as head of the immuno-pharmacology team. Prior to joining Pfizer, Dr. Jooss served as vice president of research at Cell Genesys, Inc., or Cell Genesys, from June 2005 to April 2009, and as senior director of research at Cell Genesys from July 2001 to June 2005. She is on the editorial board of Molecular Therapy and the Journal of Gene Medicine and is a member of the Immunology and Educational Committee of the American Society of Gene & Cell Therapy and the Industry Task Force of the Society for Immunotherapy of Cancer. Dr. Jooss received her diploma in theoretical medicine from the University of Marburg in Germany, a Ph.D. in molecular biology from the University of Marburg in Germany and performed postgraduate work in gene therapy and immunology at the University of Pennsylvania.
|Jonah Rainey, PhD||Gritstone Oncology Inc|
Vice President Antibody Therapeutics
Dr. Jonah Rainey is currently the Vice President for the Antibody Therapeutics department at Gritstone Oncology. Previously, he was the CEO of Oriole, a consulting and research organization focused on discovery through early development of biologic in San Diego. He holds a PhD in Biochemistry from Tufts University and completed postdoctoral training at the University of Wisconsin and the Salk Institute. He has been actively engaged in discovery, research, and development of bispecific antibodies in a biotech setting for 12 years. He is an inventor on several patents and applications describing novel bispecific platforms as well as current clinical candidates that exploit these platforms. Dr. Rainey led or had major contributions to research and early development of at least three current clinical candidates in phase 1 and 2, and led many additional advanced preclinical programs in oncology, infectious disease, autoimmunity, and other therapeutic areas. Industry experience spans small biotech (MacroGenics, MabVax) and large pharma settings (MedImmune/Astrazeneca).
|Alexis Bloom||Gyroscope Therapeutics|
Vice President Regulatory Affairs
Alex Bloom serves as VP Regulatory Affairs and Quality Assurance at Gyroscope Therapeutics, a UK-headquartered company focused on developing products and surgical delivery devices to preserve sight and fight the devastating impact of blindness. Gyroscope’s leads investigational gene therapy, GT005, is in development to treat the leading cause of blindness, dry age-related macular degeneration (dry AMD). Prior to Gyroscope, Alex has spent the past decade working on the development and regulation of cell and gene therapies. He has worked on over 40 ATMP programs, including as the regulatory lead for Holoclar®, the first stem cell-based medicine to receive approval in the West. Prior to working in Regulatory Affairs, Alex spent time in manufacturing and process development positions for recombinant protein products. He received his PhD from the University of Sheffield (UK).
|Renee Tobias||Halo Labs|
After earning her Masters in Cell and Molecular Biology, Renee worked several years in drug discovery research at companies like Tularik (Amgen), Bayer, and Schering-Plough. She eventually left the bench to pursue more customer-facing roles in applications and product management for life science analytical tools. She is passionate about promoting new, innovative solutions to accelerate biopharmaceutical development, and her current role as Director of Marketing at Halo Labs enables her to do just that.
|Xiaomai Zhou||Hangzhou DAC Biotech Co Ltd|
Vice President Biology
Dr. Xiaomai Zhou obtained his Ph.D. Degree from Dr. Lew Cantley’s Lab at Tufts University, and did his postdoctoral research in Dr. Joan Brugge’s Lab at ARIAD Pharmaceuticals. He has worked 12 years on ADC research at ImmunoGen, Inc., and 5 years on exploratory therapeutic antibodies at Boehringer Ingelheim. Dr. Zhou has been the Vice President at Hangzhou DAC Biotech in the past 6 years, leading the company's efforts in molecular and cell biology, antibody engineering and production processes, as well as cell-based ADC functional evaluation. He has been involved in leading a series of new ADC projects with the company’s intellectual properties. The first innovative ADC is in phase I clinical trials, and this presentation will be on the attractive features and promising results of the second ADC drug.
|George Church, PhD||Harvard Medical School|
Robert Winthrop Professor, Genetics
George M. Church, PhD ’84, is professor of genetics at Harvard Medical School, a founding member of the Wyss Institute, and director of PersonalGenomes.org, the world’s only open-access information on human genomic, environmental, and trait data. Church is known for pioneering the fields of personal genomics and synthetic biology. He developed the first methods for the first genome sequence & dramatic cost reductions since then (down from $3 billion to $600), contributing to nearly all “next generation sequencing” methods and companies. His team invented CRISPR for human stem cell genome editing and other synthetic biology technologies and applications – including new ways to create organs for transplantation, gene therapies for aging reversal, and gene drives to eliminate Lyme Disease and Malaria. Church is director of IARPA & NIH BRAIN Projects and National Institutes of Health Center for Excellence in Genomic Science. He has coauthored 450 papers, 105 patents, and one book, “Regenesis”. His honors include Franklin Bower Laureate for Achievement in Science, the Time 100, and election to the National Academies of Sciences and Engineering.
|Andrew Kruse, PhD||Harvard Medical School|
Assistant Professor, Biological Chemistry & Molecular Pharmacology
Andrew Kruse an Associate Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. Prior to joining the faculty at Harvard, he completed doctoral training with Brian Kobilka at Stanford University where he studied neurotransmitter receptor structure and pharmacology. Research in the Kruse lab focuses on structure and mechanisms of transmembrane signaling proteins, with a particular emphasis on the development and application of antibody fragments as tools to study signaling receptors. Dr. Kruse is the recipient of a Smith Family Award for Excellence in Biomedical Research, a Klingenstein-Simons Fellowship, a Vallee scholar award, and an NIH Director’s Early Independence Award.
|Mahmoud Nasr, PhD||Harvard Medical School|
Instructor, Biological Chemistry & Molecular Pharmacology
I received a PhD in pharmaceutical Sciences from Northeastern University, and postdoc fellowship training at Harvard Medical School. Currently, I’m a group leader at Brigham and Women’s hospital in the Engineering in Medicine Division, Department of Medicine.
|Torsten Hechler, PhD||Heidelberg Pharma Research GmbH|
Vice President ADC Research, Cell Biology & Biochemistry
Dr. Torsten Hechler is the Vice President ADC Research and as such Head of Biochemistry, Bioanalytics and Cell Biology at Heidelberg Pharma Research GmbH, a pharma company located near Heidelberg (Germany), mainly conducting research and development of anti-cancer drugs. He obtained his diploma degree in biology in 2003 followed by a PhD in microbiology at the Technical University Darmstadt. For his postdoctoral studies at the German Cancer Research Center (DKFZ) in Heidelberg he switched in 2008 the field towards virology. In 2011 he joined the team of Heidelberg Pharma as a group leader and started his work on the development of new ADCs based on the RNA polymerase II inhibitor alpha-Amanitin. He is currently responsible for the ADC Research at Heidelberg Pharma with focus on the development of new Amanitin based ADCs for clinical development.
|Johannes Van den Heuvel, PhD||Helmholtz Center for Infection Research|
Research Group Leader, Recombinant Protein Expression
I am a Biochemist and did my PhD in Biotechnology in Amsterdam at the Free University. Since 1990 I developed my career in protein expression and purification, starting at the German Research Institute for Biotechnology (GBF) in Braunschweig Germany investigating gene expression and biochemical engineering. After the renaming of the institute into the Helmholtz Centre for Infection Research (HZI) my research focus changed to integrative structural biology. I am currently Head of the Protein Sample Production Facility (PSPF) at the HZI and Research Group Leader for recombinant protein expression.
|Simon Lacey||Hospital of the University of Pennsylvania|
Director, Center for Cellular Immunotherapies, Translational & Correlative Studies Lab
In 1998 Dr. Lacey moved to the Beckman Institute of the City of Hope, where, as an Associate Research Professor and Principal Investigator in Don Diamond’s Laboratory of Translational Vaccine Research, he studied viral and tumor immunity. During this period he was the recipient of investigator awards from the Leukemia and Lymphoma Society, NIAID and NIDDK. In 2010, he assumed the Directorship of the Clinical Immunobiology Studies Laboratory at the Beckman Institute. In 2012 he moved to the University of Pennsylvania, where he is currently Director of the Translational and Correlative Studies Laboratory. The TCSL supports numerous Phase I and II trials of engineered cellular therapies for cancer, infectious and autoimmune disease by performing molecular, cellular and biochemical assays on manufactured cellular products and on patient samples.
|Dennis Karthaus, MSc||IBA Lifesciences|
Director Protein Products & Assays
Dennis Karthaus received his master`s degree in biotechnology from the Univ. of Applied Sciences in Bremerhaven. During his thesis he worked on the development of protein purification platforms and in cell line development. In 2012, Dennis Karthaus joined IBA Lifesciences. He's leading the department for protein purification & assays and is responsible for the development of products & technologies for protein expression, purification and analysis.
|Birgit Viira||Icosagen Cell Factory OU|
Key Account & Technology Officer
No bio available
|Ramon Alemany, PhD||IDIBELL|
Researcher Cancer Virotherapy, Cancer & Human Molecular Genetics
Ramon Alemany did his PhD in Biology at the University of Barcelona. Since 1993, he held postdoctoral positions at the MD Anderson Cancer Center, Baxter Healthcare, and the University of Alabama at Birmingham. In 2001, he joined the Catalan Institute of Oncology/Institute of Biomedical Research of Bellvitge. He is author of numerous papers on oncolytic adenoviruses, co-founder of VCN Biosciences, and former President of the Spanish Society of Gene and Cell Therapy.
|Bruce Keyt, PhD||IGM Biosciences Inc|
Bruce received his Ph.D. in biochemistry and pharmacology from Tufts University School of Medicine and his B.S. in Chemistry from Washington University in St Louis. He is a co-inventor on more than 35 U.S. patents and patent applications, and he has a co-authored more than 55 scientific articles. Bruce brings to IGM more than thirty-five years of research, development and management experience in large and small biotechnology companies, including his extensive experience in many phases of early stage drug discovery and development. This experience spans target selection and discovery, in vitro biochemistry, in vivo efficacy models and all other aspects of the pre-clinical development of antibodies and proteins as therapeutic agents.
|Robert Lutz||Iksuda Therapeutics|
Bob Lutz serves as Chief Scientific Officer of Iksuda Therapeutics and has extensive experience in the development of antibody-based therapeutics. With more than 25 years’ experience, Bob was previously Vice President of Translational Research and Development at ImmunoGen, where he was responsible for all early-stage ADC development programs and directly the clinical pharmacology, biomarkers, pharmacology and toxicology departments. While at ImmunoGen, Bob was responsible for bringing multiple ADC candidates through development and was ImmunoGen’s research lead for the FDA-approved trastuzumab emtansine.
|An Song||Immune Onc Therapeutics|
Chief Scientific Officer
An Song, Ph.D, is Senior Vice President of Development Sciences at Immune-Onc Therapeutics, Inc., accountable for translational development of Immune-Onc’s portfolio, including preclinical PKPD and toxicology evaluation, clinical pharmacology, bioanalytical and biomarker/diagnostic development and certain analytical aspects of technical development. Prior to Immune-Onc, An was a Senior Director in BioAnalytical Sciences at Genentech, where she led the Assay Development and Technology group for the company’s large molecule portfolio globally. During her 16-year tenure at Genentech, An contributed to, and oversaw 40+ IND/CTA and BLA/MAA regulatory filings for products including Rituxan@, Avastin®, Herceptin®, Lucentis ®, Kadcyla®, and Tecentriq®. Additionally, she played a significant role for the development and approval of Ocrevus®.
An holds a B.S. in Biochemistry from Nanjing University in China. She received her PhD. in Biochemistry & Molecular Biology from Indiana University and completed a postdoctoral fellowship in immunology at Stanford University. Upon completion of postdoctoral work in T-cell activation she joined Stanford as a Research Assistant Professor and as faculty of the Immunology Program. An has published a number of original manuscripts, review articles and book chapters, as well as contributed to several industry white papers on immunogenicity and antibody Fc effector function evaluation. She is an active member of American Association of Pharmaceutical Scientist (AAPS), having served as an executive member of the Biotech Section and the chair of Therapeutic Product Immunogenicity (TPI) Focus Group/Community.
|Anton Neschadim||ImmunoBiochem Corp|
President & CEO
Anton is a biomedical professional, scientist, innovator, entrepreneur and venture capitalist with more than 15 years of industry and academic experience in research and drug development. At ImmunoBiochem Corporation, Anton is leading the development of a new class of tumor microenvironment-targeted anti-cancer therapeutics. Anton was formerly the Director of Drug Development at Armour Therapeutics Inc., a biopharmaceutical company developing a new class of anti-cancer therapeutics for prostate, breast and ovarian cancers. Throughout his career, Anton worked on R&D and consulting projects with several biopharmaceutical companies developing biological therapeutics and immunotherapies in oncology. Anton has expertise in cancer research, immunology, chemistry, regenerative medicine and gene therapy, and authored more than 25 peer-reviewed publications and patents. Anton obtained his PhD, MSc, and Hon. BSc degrees in medical biophysics, immunology, and biological chemistry at the University of Toronto, where he also completed postdoctoral work and his MBA at the Rotman School of Management. Anton was also a trainee of the CIHR Training Program in Regenerative Medicine (TPRM), Toronto General Hospital, University Health Network. Anton was a founding board member, and former CCO and organizing committee member of the Canadian Science Policy Centre (Toronto, ON) – a national organization promoting science policy in Canada. Anton has led several venture capital investments in biomedical and healthcare companies at GreenSky Capital.
|Sofie Pattijn||ImmunXperts SA|
Founder & CTO
Sofie Pattijn (CTO and founder, ImmunXperts) has over 20 years of experience in the field of immunogenicity assessment (vaccines and biotherapeutics) and in vitro assay development. She has extensive hands-on lab experience and has managed and coached several In Vitro teams over the last decade. From 2008 till 2013 she was Head of the In Vitro Immunogenicity group at AlgoNomics (Ghent, Belgium) and Lonza Applied Protein Services (Cambridge, UK). Prior to that, she worked at Innogenetics, Belgium for over 15 years.
|Lawrence Lamb Jr||Incysus Therapeutics Inc|
Executive Vice President & CSO
Dr. Lamb was first to describe the association between relapse-free survival and gdT cell recovery in bone marrow transplant patients. For 26 years, most recently as Professor of Medicine and Director of the Cell Therapy Laboratory at the University of Alabama at Birmingham, Dr. Lamb developed the scientific support for gdT cell-based immunotherapies. Today, this work has brought us to the first clinical trials for allogeneic gdT cell therapy in leukemia patients undergoing haploidentical stem cell transplants and the first gene-modified gdT cell therapy for glioblastoma. Dr. Lamb currently directs clinical and translational research strategy and operations for Incysus Therapeutics.
|Patrick Mayes||Incyte Corp|
Executive Director & Head, IO Antibody Research
Patrick Mayes, PhD, is Executive Director, Head of Biotherapeutic Research at Incyte. Dr. Mayes was previously Director of Biology and was an Early Development Leader for the Immuno-Oncology and Combinations discovery performance unit at GlaxoSmithKline. He has developed novel therapeutic antibodies which modulate innate and adaptive immune responses utilizing a variety of biotherapeutic platforms including Fc-engineered monoclonal antibodies (mAbs), bi-specific mAbs, domain antibodies (dAbs) and antibody-drug conjugates (ADCs) and has initiated and lead programs combining immune targeted therapies as well as others combining immunotherapies with tumor targeted agents.
|Horacio Nastri, PhD||Incyte Corp|
Executive Director Antibody Discovery
No bio available
|John Lambert||Independent Consultant|
Dr. Lambert graduated from Christ’s College, University of Cambridge (England, UK), with a degree in Natural Sciences in 1972. He then went on to earn a Ph.D. in Biochemistry (1976) from the University of Cambridge, working on enzyme structures under the supervision of Professor Richard N. Perham. Dr Lambert’s postdoctoral training was at the University of California, Davis, working on ribosome structure in the laboratory of Dr Robert R. Traut (1976-1980), and at the University of Glasgow, Scotland working on the arom multienzyme complex in the laboratory of Dr John R. Coggins (1980-1982). In 1982, Dr. Lambert joined the Dana-Farber Cancer Institute, Harvard Medical School, working on the ImmunoGen-funded programs to develop antibody-drug conjugates (ADCs) and immunotoxins as anti-cancer therapeutics. Dr. Lambert joined ImmunoGen in 1987 when the company established independent research laboratories in Cambridge, Massachusetts. After working in a variety of roles at the company, Dr. Lambert served as Chief Scientific Officer from 2008 until 2015. In 2016, he became a Distinguished Research Fellow at the company until his retirement at the end of 2017. He served on the Executive Committee of the company as Executive Vice President, Research, from 2008 until 2016, followed by a year (2017) on the Executive Committee in an Emeritus capacity. During Dr Lambert’s tenure in leadership roles at ImmunoGen, the company invented the ADC technology that resulted in the Genentech/Roche drug, Kadcyla® (approved in 2013 for treating HER2+ breast cancer), as well as numerous other ADCs taken into clinical development. One of these is ImmunoGen’s promising drug candidate, mirvetuximab soravtansine, an ADC currently in a phase 3 trial for the treatment of platinum-resistant ovarian cancer. Dr Lambert is the author/co-author of over 120 peer-reviewed scientific publications. In 2016, Dr Lambert was elected as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). In 2018, he was appointed as an Honorary Professor of Queen’s University, Belfast, Northern Ireland, UK.
|Martin Jarrold||Indiana University|
Martin F Jarrold obtained his undergraduate and graduate degrees from the University of Warwick in England, and then went to the University of California, Santa Barbara as a NATO Postdoctoral Fellow. After several years in California, he joined the Physics Research Division of AT&T Bell Laboratories in Murray Hill, New Jersey. In 1992, he moved to Northwestern University to become a Professor in the Chemistry Department. While at Northwestern he performed pioneering work on ion mobility mass spectrometry. In 2002 he moved to Indiana University as Professor and Robert and Marjorie Mann Chair. His recent work at IU has focused on developing charge detection mass spectrometry.
|Nathan Alves||Indiana University School of Medicine|
Asst Prof, Emergency Medicine
Dr. Alves received his PhD in Chemical and Biomolecular Engineering from the University of Notre Dame. The research he conducts, while spanning many disciplines, is centered on the development of translational technologies, treatments, and techniques that can be utilized to have a positive impact on people’s lives. He has extensive experience in: site-specific antibody modification, oriented antibody immobilization for advanced diagnostics, nanoparticle delivery, and packaging of pharmaceutical agents/enzymes to treat various diseases. Currently, Dr. Alves is an Assistant Professor at the Indiana University School of Medicine in the Department of Emergency Medicine with a joint appointment at Purdue in Biomedical Engineering. His multidisciplinary background affords him a unique perspective to tackle complex medical device and therapeutic development problems.
|David Bramhill, PhD||Individual Consultant|
Dr. Bramhill has over 20 years’ experience in biologics, both in large biopharma and startup biotech companies. He has expertise in isolating and improving antibodies using phage display and other display systems and is an inventor on library design for small scaffolds and bi-specific formats. He also has experience in diverse expression systems for producing antibodies, antibody fragments and scaffolds. He has taught numerous technical courses for over 15 years at international conferences and served as a Key Opinion Leader for major BioPharma companies.
|Raymond Tesi||INmuneBio Inc|
CEO & CMO
After an academic career as a transplant surgeon, RJ Tesi joined industry to develop novel therapies to manipulate the immune system; first focusing on immunosuppression and autoimmunity within the adaptive immune system and more recently on the innate immune system in cancer and neurodegenerative diseases. Dr. Tesi is the CEO and CMO of INmune Bio, a NASDAQ company (INMB).
|Salvatore Valitutti, MD||INSERM Transfert|
Salvatore Valitutti, MD, former full professor of immunology at the University of Toulouse, France is Director of Research at INSERM. He has been working for more than twenty years on T lymphocyte activation by antigenic determinants displayed on antigen presenting cell (APC) surface and has acquired uncommon expertise on in vitro and in tissue study of human primary immune cells. Dr. Valitutti has been member of the Basel Institute for Immunology in Basel, Switzerland where he contributed to the understanding of basic mechanisms of T lymphocyte activation. More recently, in Lausanne (Switzerland) and in Toulouse (France), Dr. Valitutti has contributed to define the structure, dynamics and function of immunological synapses, formed by both helper and cytotoxic T cells. His research team develops, at the INSERM U1043 in Toulouse, a multi-disciplinary research program in which, biologists in collaboration with clinicians, computer scientists and mathematicians, investigate different aspects of the intercellular communication occurring at immunological synapses in human health and disease.
|Ross Chambers, PhD||Integral Molecular Inc|
Vice President, Antibody Discovery
Ross Chambers is Vice President of Antibody Discovery at Integral Molecular. He pioneered the use of DNA immunization for antibody production and developed Integral Molecular’s B-cell cloning system for antibody isolation. Before joining Integral Molecular, Dr. Chambers was Director of R&D at SDIX, where he directed the discovery of thousands of commercial antibodies.
|Benjamin Doranz, PhD, MBA||Integral Molecular Inc|
President & CEO
Ben Doranz (President and CEO, Integral Molecular) has expertise in membrane proteins and antibodies, with 80+ publications, in journals including Cell, Science, and Nature. Dr. Doranz cofounded the company and has led all aspects of the company’s growth since its inception, bringing five different technologies from research to market.
|Jonathan Davis, PhD||Invenra Inc|
Head of Innovation, Innovation & Protein Engineering
Jonathan Davis, PhD is Head of Innovation at Invenra, Inc. Headquartered in Madison, Wisconsin, Invenra is focused on discovery and development of human IgG-like multispecific antibodies for immuno-oncology and autoimmune disorders. A thought leader in the field of bispecific antibodies for over a decade, Dr. Davis has 18 years of industry experience (Bristol-Myers Squibb, EMD Serono) as a protein engineer and platform developer focusing on antibodies and multispecific biotherapeutics, covering a wide variety of therapeutic areas. Dr. Davis holds a PhD in biophysics from UC San Francisco, which he followed with a postdoctoral fellowship at Harvard Medical School.
|John McCafferty, PhD||IONTAS|
CEO & Founder
John McCafferty was one of the founders of Cambridge Antibody Technology (CAT, now Medimmune) in 1990 and published the first paper/patent describing antibody phage display. After 12 years at CAT he returned to academia at the Sanger Institute and the University of Cambridge. In 2012 John formed IONTAS, a small innovative biotechnology company using phage display to develop novel antibody therapeutics. IONTAS have also developed a novel technology for construction of very libraries in mammalian cells by using CRISPR/Cas 9 and TALE nucleases to efficiently direct the integration of a library of antibody genes into single genomic locus within a population of cells.
Director, Regulatory Affairs
William leads the orphan drug unit within GRA and serves as the US Agent for multiple Investigation of New Drugs, New Drug Applications and Supplements. William provides strategic advice to clients on regulatory strategy, leads regulatory projects and specialty designation requests, provides CMC technical writing and reviews for new applications (INDs, NDAs, BLAs) in rare disease space; interacts with Regulatory Agencies (FDA, Heath Canada, etc.) He has also served as the Regulatory Project lead for numerous NDA 505(b)(2) applications approved by the US FDA.
William has prepared NDA 505(b)(2), INDs, supplements and life cycle management submissions (in eCTD) with an emphasis in CMC for NDAs and INDs. He has provided RA Assessments for change control for pharmaceutical products ensuring regulatory compliance, as well as CMC strategies as they relate to new applications and supplements. He has completed GAP analyses as they relate to CMC content. William is familiar with the requirements for pharmaceutical labelling to ensure that it is sufficient for submission to FDA (container labels, package inserts and metadata for SPL format). He has knowledge of regulations in Asia Pacific and Latin America for both pharmaceuticals and medical devices.
|Rajkumar Ganesan||Janssen Pharmaceuticals Inc|
Director, Antibody Engineering, Bispecifics & CAR T
Raj Ganesan received his Ph.D. at the University of Zurich, Switzerland. Raj is a Protein/Antibody engineer with extensive industry experience (Genentech, MedImmune and Boehringer Ingelheim) in the Design, Development and Characterization of Monoclonal Antibodies, Multi-Specific Biologics and CAR-T. Since 2017, Raj is leading the pre-clinical discovery of biotherapeutics at Janssen R&D (Johnson and Johnson), primarily focused on bispecific antibodies and CAR-T therapies.
|Elissa Leonard||Johns Hopkins University|
PostDoctoral Research Fellow, Biomedical Engineering
Dr. Elissa Leonard attended Harvery Mudd College, where she received her B.S. in Biomolecular Systems and Design, and developed novel bioreactor designs for corneal tissue engineering with Dr. Elizabeth Orwin. She earned her Ph.D. at the University of Texas at Austin, where her research focus shifted to engineering therapeutically relevant autoimmune T cell receptors under the supervision of Dr. Jennifer Maynard. Currently, Dr. Leonard is a Postdoctoral Fellow at Johns Hopkins University, where she has continued research in protein and immune engineering with Dr. Jamie Spangler. Currently, her work focuses on engineering antibody-cytokine fusion proteins that can shift the immune balance and promote anti-tumor or pathogen-clearing immune activity. She is also revisiting her regenerative engineering roots by engineering of growth hormones for applications in osteogenesis.
|Jamie Spangler||Johns Hopkins University|
Assistant Professor, Biomedical Engineering
Dr. Jamie Spangler earned a Bachelor of Science degree in Biomedical Engineering at Johns Hopkins University and went on to complete a PhD in Biological Engineering at MIT under the supervision of Professor K. Dane Wittrup. She conducted postdoctoral training in Professor K. Christopher Garcia’s lab at Stanford University School of Medicine, and then launched her independent research group at Johns Hopkins University in July 2017, jointly between the departments of Biomedical Engineering and Chemical & Biomolecular Engineering. Dr. Spangler’s lab, located in the Translational Tissue Engineering Center at the School of Medicine, applies structural and mechanistic insights to re-engineer existing proteins and design new proteins that therapeutically modulate the immune response. In particular, her group is interested in engineering immune molecules such as antibodies, cytokines, and growth factors for targeted treatment of diseases such as cancer, infectious diseases, and autoimmune disorders. Dr. Spangler’s work has been recognized with honors including a National Defense Science and Engineering Graduate Fellowship, a Leukemia & Lymphoma Society Career Development Fellowship, a V Foundation Scholar award, and a Maryland Stem Cell Research Fund Discovery award.
|Jean Stanton||Johnson & Johnson Pharmaceutical R&D|
Director, CAR T Site Liaison
Jean joined Johnson and Johnson in 2008 after more than 20 years in the health care industry, at a university based medical institution, developing cell-based therapies. During that time, she was responsible for leading the integration of cell and gene therapy regulations into J&J’s internal quality standards. She developed internal training programs to educate organizations within the Pharmaceutical and Medical Device Sectors of J&J. She also played a key role in the development of J&J’s compliance strategies relating to cell-based products. Jean’s responsibilities included; the deployment and maintenance of the R&D compliance program for all GMP aspects within J&J’s Pharmaceutical Sector and the development of the quality and compliance strategies to support all new platforms that are in-licensed or developed within the Sector.
More recently, Jean assumed a new role in Apheresis Operations, supporting cell collections used in CAR-T manufacturing and leading internal efforts to build organizational infrastructure in support these novel products.
|Elizabeth Trehu||Jounce Therapeutics Inc|
Elizabeth (Beth) G. Tréhu, M.D, FACP, is Chief Medical Officer of Jounce Therapeutics, a clinical stage immuno-oncology company dedicated to transforming the treatment of cancer by matching the right immunotherapy to the right patient. Dr. Tréhu designed and conducted her first cancer immunotherapy clinical trials in the early 1990s as an assistant professor and translational researcher at Tufts University School of Medicine, where her research focused on reducing the toxicity of high dose interleukin-2. She has held oncology leadership positions in drug development from IND through post-marketing at Millennium Pharmaceuticals, Genzyme Corporation, Infinity Pharmaceuticals, and Promedior, Inc. and joined Jounce in 2015 to build and lead the clinical organization.
|Julija Mezhyrova, MSc||JW Goethe University|
Julija Mezhyrova studied Biochemistry at the Goethe University Frankfurt and gained additional practical experience at the Paul Ehrlich Institute in Darmstadt and at Harvard Medical School in Boston. She is currently working on her PhD thesis at the Goethe University Frankfurt at the Institute of Biophysical Chemistry. Focus of her thesis is the characterization of bacteriolytic phage proteins, being promising targets for future antibiotic development and for industrial applications in the vaccination of livestock.
|Ho Leung Ng, PhD||Kansas State University|
Associate Professor, Biochemistry & Molecular Biophysics
Ho Leung Ng completed his BA at Harvard University, PhD at UCLA, and postdoctoral fellowship at UC Berkeley in the areas of structural biology and crystallography. After leaving UC Berkeley, Dr. Ng worked with Brian Kobilka at ConfometRx on GPCR crystallography. Dr. Ng then moved to the University of Hawaii as an Assistant Professor and later to Kansas State University as Associate Professor. His current research focuses on experimental and computational structure-based drug design for GPCRs, nuclear receptors, and kinases. Dr. Ng is also interested in applications of machine learning for chemistry and drug design.
|Susanne Graslund, PhD||Karolinska Institute|
Senior Researcher, Medical Biochemistry & Biophysics
Susanne Gräslund did her doctoral training in Biotechnology at the Royal Institute of Technology in Stockholm, Sweden. After her dissertation in 2002 she worked for three years at Biovitrum AB in the Target Expression & Purification section. In March 2005, Susanne joined the newly started Structural Genomics Consortium group in Stockholm, heading the Biotechnology team responsible for the generic protein production pipeline. She was then recruited to the SGC Toronto site as Principal Investigator for the Biotechnology team in September 2011. In 2015, SGC established a new lab at Karolinska Institutet in Stockholm where Dr. Gräslund is now leading a new team to generate recombinant antibodies for target validation and research purposes.
|Amber Fradkin||KBI Biopharma|
Director, Particle Characterization Core Facility
Amber received her PhD in Chemical Engineering within the Pharmaceutical Biotechnology Program with a specialization in the field of immunogenicity of therapeutic protein aggregates at the University of Colorado at Boulder. Amber also holds a Masters in Science from the University of Colorado at Boulder plus a Bachelors of Science from the Colorado School of Mines. She currently holds the position of Director at KBI Biopharma where she manages the Particle Characterization Core which specializes in analytical methods for quantifying, characterizing and identifying submicron, subvisible and visible particulates. Previously, at Amgen, Amber was a Scientist within the biomolecular structures and interactions group where she supported biophysical characterization of protein products with a specialty in subvisible particle characterization and identification. Prior to Amgen, Amber’s experiences include analytical and formulation development for Merck & Co. and collaborations with BaroFold, Inc. to employ high hydrostatic pressure to refold proteins and control subvisible particles.
|Adrian Bot, MD, PhD||Kite Pharma Inc|
Vice President Translational Medicine
Adrian Bot, M.D., PhD is the Vice President of Translational Sciences at Kite, a Gilead Company. Kite is a biotechnology company developing genetically engineered T cell therapies, based in Los Angeles, CA. He has more than 20 years of experience in biomedical research and development. Dr. Bot obtained his M.D. at the University of Medicine and Pharmacy in Timisoara – Romania and his PhD in Biomedical Sciences at Mount Sinai School of Medicine in New York. Subsequently, he was a Guest Scientist at the Scripps Research Institute in La Jolla and Scientist, Principal Scientist and Director of Immunology Research at Alliance Pharmaceutical Corp. in San Diego. In Nov 2002, Dr. Bot joined Allecure Pharmaceuticals which became MannKind Corp, where he was a Director of Research and Development. He had several other appointments at MannKind: Sr. Director of Translational Medicine, Vice President of Scientific Management and Vice President of Research, prior to the appointment first as Chief Scientific Officer and then Vice President of Translational Sciences at Kite.
|Thariska Tharmakulasingam||Kuhner Shaker AG|
Specialist, Orbital Bioreactors
No bio available
|Alessandro Sette||La Jolla Institute for Allergy & Immunology|
Professor & Center Head
Dr. Alessandro Sette has devoted more than 30 years of study towards understanding the immune response, measuring immune activity, and developing disease intervention strategies against cancer, autoimmunity, allergy, and infectious diseases. The laboratory is defining in chemical terms the specific structures (epitopes) that the immune system recognizes and uses this knowledge to measure and understand immune responses.
|Paul Parren, PhD||Lava Therapeutics|
Executive Vice President & Head
Prof. Paul W.H.I. Parren, (Lava therapeutics) is dedicated to translating antibody biology and immunotherapy knowledge into innovative therapeutics and technologies. Prof. Parren studied Biology at the University of Amsterdam where he obtained a M.Sc. in Experimental Oncology (cum laude) in 1987 and a PhD in 1992. Next, he was a Postdoc, Assistant Professor and Associate Professor in the department of Immunology at The Scripps Research Institute in La Jolla, California, where he interrogated the human antibody response in protection against viral infections. From 2002-2017, he served in the positions of Vice President, Senior Vice President and Scientific Director at the biotechnology company Genmab in Utrecht, where he headed preclinical R&D leading to the development of the approved therapeutic antibodies ofatumumab (Arzerra) and daratumumab (DARZALEX), and several clinically translated technologies aimed at improving antibody therapy including bispecific and effector-function enhanced antibodies. In 2015, he became a Professor of Molecular Immunology at the Leiden University Medical Center in Leiden. Since 2018, he is EVP and head of R&D at the biotech Lava Therapeutics where he develops novel bispecificT-cell engagers for cancer therapy. He also provides drug development, patent and investment advice as an independent biotech consultant.
|Matthew Coleman, PhD||Lawrence Livermore Natl Lab|
Senior Scientist & Group Leader
Dr. Coleman is a senior biomedical staff scientist at Lawrence Livermore National Laboratory and an adjunct professor in the department of Radiation Oncology at University of California Davis School of Medicine and. He received his Ph.D. in molecular biochemistry and cellular biology from Boston University. Dr. Coleman has authored over 150 publications in peer-reviewed journals, published proceedings and book chapters covering a diverse breadth of molecular biology and biochemistry. He has over 19 years of experience in developing biotechnology and characterizing genomic responses of genotoxic stressors such as ionizing radiation.
|Jeiwook Chae, PhD||LegoChem Biosciences|
Chief Business Development Office
Since earning his Ph.D. from University of Virginia, Dr. Jeiwook (Jei) Chae has conducted research both in academic and industry settings, gaining invaluable experience in many aspects of discovery research, animal models for human diseases, and preclinical therapeutic testing. His postdoctoral research at Harvard University was primarily focused on elucidating the mechanism underlying spreading RNAi signals between cells, especially related to cancer biology. His collaborative preclinical research with a leading RNAi therapeutics company, Alnylam, provided important insights for the clinical development of RNAi therapeutics. Subsequently, he joined Bioneer, where he served as Director of Research and conducted preclinical evaluations of a siRNA-based drug technology as well as research into RNAi pipelines involving multiple diseases. As Chief Business Development Officer and VP of Biology at LegoChem Biosciences Dr. Chae currently leads company’s scientific endeavors and has guided academic and industry collaborations, advancing clinical development of pipeline programs including antibiotics, anti-fibrosis, and Antibody-Drug Conjugates (ADC)-based cancer drugs. He has successfully executed transactions with Takeda/Millennium ($404M+ licensing and collaboration agreement for multi-target antibody-drug conjugate, Mar 2019) and Fosun Pharma (licensing agreement for HER2-targeted ADC, Aug 2015).The primary mission of Dr. Jei Chae and his colleagues in LegoChem Biosciences is to develop a clinically validated ADC drugs using ADC platform technology developed by the company including novel site-specific conjugation and proprietary cancer-selectively activated linker and payload.
|Wim Jiskoot, PhD||Leiden University|
Professor, Drug Delivery Technology
Wim Jiskoot is professor at the Division of BioTherapeutics at Leiden University (since 2006), the Netherlands, and scientific advisor at Coriolis Pharma, Martinsried, Germany (since 2013). His main research area is biologics formulation. He coedited 3 books about protein characterization and (co)authored over 300 scientific papers and book chapters.
|Cornelis Sier||Leiden University Medical Center|
Senior Researcher, Image Guided Surgery
Kees (short for Cornelis) is a molecular biologist especially focused on cell-cell interactions in cancer. He studied molecular biology in Amsterdam (NL) and obtained his PhD in 1993 at the Leiden University Medical Center, investigating the role of proteinases in cancer. After a post-doc in Leiden, he continued his work at the Università Vita Saluta San Raffaele in Milan (IT). In his Italian period, he visited the Mario Negri Institute for Pharmacological Research in Milan (IT) and the Finsen Laboratory, a basic cancer research unit in Copenhagen (DK). He returned to Leiden performing cancer-related research projects in the departments of Pathology, Gastroenterology, and Surgery. In 2010, Kees joined the Image-guided Oncologic Surgery group (Head, dr. Alexander Vahrmeijer) within the department of Surgery. His main focus is the evaluation of tumor markers as target for image-guided surgery and the subsequent development of tracers against selected candidates.
|William Gillette, PhD||Leidos Biomedical Research Inc|
Principal Scientist Protein Expression Lab, Cancer Research Technology Program
I am currently leading the recombinant protein production efforts of the RAS Initiative at the Frederick National Laboratory in Frederick, MD.
|Dina Schneider||Lentigen Technology Inc|
Associate Director Translational Research
Dina Schneider, Ph.D., is a scientist and an inventor with over-15 years of experience in academia and industry. Dr. Schneider earned her Ph.D. from Michigan State University, and completed her postdoctoral training at the University of Michigan. Her academic career spanned diverse areas of interest, including cellular and molecular immunology, immunotoxicology, inflammation, and molecular biology. In 2011, Dr. Schneider transitioned to industry, where she contributed to numerous projects in synthetic immunology, immunotherapy, and chimeric antigen receptor (CAR) T cell-based therapy. Dr. Schneider leads the Translational Research group at Lentigen Technology, Inc., a Miltenyi Biotec Company, in Gaithersburg, MD. Her group is focused on pre-clinical development of novel CAR-based therapies targeting hematologic malignancies as well as solid tumors, and on the implementation of CliniMACS Prodigy® clinical platform for preparation of cell-based therapeutics. Her recent work includes the development of novel CAR therapies, three of which are now in clinical trials.
|Stephen Demarest, PhD||Lilly Research Labs|
Research Advisor, Protein Biosciences
Steve leads a group at Lilly responsible for the design, engineering, and mechanistic characterization of proteins, antibodies, and antibody-like molecules. Prior to joining Lilly in 2011, Steve held positions at Biogen Idec, Diversa Corp, and Syngenta working as a Protein Chemist/Engineer on antibody and protein therapeutics design and biochemistry. Steve performed his graduate work at SUNY Stony Brook studying protein folding mechanisms. Steve was a NIH sponsored postdoctoral fellow at the Scripps Research Institute studying the structure, folding, and binding of nuclear co-activator proteins.
|Dennis Krieg||Ludwig Maximilians University|
Graduate Student, Pharmacy
Dennis Krieg is a pharmacist by training and Ph.D. student in the research group of Prof. Dr. Gerhard Winter at the Ludwig-Maximilians-University Munich, Germany. In his thesis, Dennis focuses on different aspects of protein co-formulations. His work includes the analytical characterization, formulation development, stability testing and interaction studies of co-formulations for therapeutically relevant cytokines, enzymes and antibodies.
|Alexey Berezhnoy, PhD||MacroGenics Inc|
Alexey Berezhnoy is a scientist in the Cell Biology and Immunology group at MacroGenics, Inc., which he joined in 2016 from a faculty position in the Department of Medicine University of Miami. Dr. Berezhnoy has been active in tumor immunology research for the past 10+ years, focusing on novel therapeutic approaches, including multi-specific molecules and tumor-targeted therapies. Dr. Berezhnoy has authored several high-impact publications in the field of immuno-oncology.
|Ezio Bonvini, MD||MacroGenics Inc|
CSO & Senior Vice President Research
Ezio Bonvini joined MacroGenics in 2003 after a career at the National Cancer Institute, NIH, and the Center for Biologics Evaluation and Research, FDA, where he last served as the Chief of the Laboratory of Immunobiology and the Acting Deputy Director of the Division of Monoclonal Antibodies. A physician by training, Dr. Bonvini is an expert in immunobiology and drug development, has authored numerous publications in the field of signal transduction, immunology and immune-oncology, and is an inventor on several patents.
|Gundo Diedrich, PhD||MacroGenics Inc|
Associate Director, Antibody Engineering
Gundo Diedrich received his PhD in Chemistry from the Max-Planck Institute for Molecular Genetics in Berlin. He completed his postdoctoral training in immunology at Yale University, and worked as a Research Scientist in antibody discovery at Targeted Molecules, diaDexus, and Medimmune. In 2015, he joined MarcoGenics as Director Antibody Engineering.
|Charlotte McDonagh||Magenta Therapeutics|
Vice President & Head, Biotherapeutics
Charlotte McDonagh joined Magenta Therapeutics in 2017 as Head of Biotherapeutics. She previously served as a vice president at Merrimack Pharmaceuticals, where she led discovery and early clinical stage programs. Prior to joining Merrimack, she led therapeutic antibody selection and engineering projects at Seattle Genetics. Charlotte holds a doctorate in biochemistry from the University of Leicester, U.K, and an undergraduate degree in biochemistry from the University of Bristol, U.K.
|Jonathan Mehtala||Malvern Panalytical|
Tech Specialist, Nanosight
No bio available
|Lucie Rochard, PhD||Massachusetts Biotechnology Council|
Liaison, Scientific & Entrepreneurial Initiatives; Director, Innovation Services,
Lucie has over ten years of experience in conducting biomedical research. She trained in Rennes, France, at the National Center for Research (CNRS) and the National Institute of Health and Medical Research (INSERM). After graduating with her Ph.D., Lucie moved to the US to complete a post-doctoral fellowship at the Massachusetts General Hospital and Shriners Hospital (joint appointment) in Boston, Massachusetts. Committed to foster alliances between Academia and Industry, to facilitate the transfer of technology for the benefit of patients, Lucie joined the largest trade association for the life Sciences, MassBio in 2017 and is Director Innovation Services. Within MassBio, in the Innovation Services team, Lucie created and now leads the Academic outreach and Engagement initiatives. Her mission is to leverage MassBio’s community of members and experts with the goal to facilitate company creation and strategic alliances within academic institutions. Over the last two years, Lucie has built several working groups convening leaders from academia and industry, as well as mentoring programs for academic scientists and joined several advisory boards to foster entrepreneurship beyond the Boston region.
|Soldano Ferrone, MD, PhD||Massachusetts General Hospital|
Professor in Residence
Soldano Ferrone received his MD and PhD degrees in 1964 and in 1971, respectively, from the University of Milan, Milan, Italy. He has held faculty positions at the University of Milan, Milan, Italy, Scripps Clinic and Research Foundation, La Jolla, CA, Columbia University, New York, NY, New York Medical College, Valhalla, NY, Roswell Park Cancer Institute, Buffalo, NY and at the University of Pittsburgh School of Medicine, Pittsburgh, PA. Since 2012 he is a faculty member of the Department of Surgery at Massachusetts General Hospital, Harvard Medical School, Boston, MA. Dr. Ferrone has received many awards and honors. For the last 30 years he has been the member of many review committees including NIH Study Sections, and of the editorial boards of many scientific journals. Furthermore, he is the member of several external scientific advisory boards. Dr. Ferrone’s research program focuses on the molecular characterization of escape mechanism(s) utilized by tumor cells to avoid immune recognition and destruction and on the development of combinatorial immunotherapeutic strategies to counteract the escape mechanism(s) utilized by tumor cells. These studies are greatly facilitated by the large panel of HLA antigen- and human tumor antigen-specific monoclonal antibodies he has developed and shared with the scientific community over the years. He has described the results of his studies in more than 600 papers published in peer reviewed journals. Moreover, he has been the editor of 14 books and the guest editor of 5 special issues of oncology journals.
|Omar Abudayyeh||Massachusetts Institute of Technology|
No bio available